• Order within –h –m
  • Free shipping on orders over $250
  • Free Bacteriostatic Water 30ml with $500+ purchase
  • Every batch tested by an independent lab
  • For laboratory and research use only. Not for human consumption

Category: Research Guides

  • What Is PT-141 (Bremelanotide)? Structure, Receptors & COA

    What Is PT-141 (Bremelanotide)? Structure, Receptors & COA

    Quick Answer

    PT-141 is the research code for bremelanotide, a synthetic cyclic peptide studied at melanocortin receptors. Seven amino acids, one ring, one well-documented structure in the public databases.

    This page sticks to the chemistry: the sequence residue by residue, the ring bond and where it falls, the molecular weight in both forms labs report, the cryo-EM structure showing the peptide inside MC4R, and a field-by-field walk through a batch certificate. Life Link Research supplies PT-141 to qualified labs for in vitro work.

    For Research Use Only. Not for use in diagnostic or therapeutic procedures. Full terms are set out in the Life Link research disclaimer.

    FieldValue
    NamePT-141, bremelanotide
    ClassCyclic heptapeptide, melanocortin ligand
    SequenceAc-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
    Molecular formulaC50H68N14O10
    Molecular weight1025.2 g/mol avg; 1024.52 Da monoisotopic
    CAS number189691-06-3 free base; 1607799-13-2 acetate
    PubChem CID9941379
    FDA UNII6Y24O4F92S
    Receptor structurePDB 7F55

    What Is PT-141?

    Quick answer: PT-141 is the research code for bremelanotide, a synthetic cyclic heptapeptide. Its seven residues carry an N-terminal acetyl group, a norleucine and a D-phenylalanine, and an Asp–Lys lactam bridge closes the ring. In research, it is studied as a melanocortin receptor agonist, mainly at MC3R and MC4R, using binding and cAMP assays.

    Two names, one molecule. PT-141 is the development code the compound picked up in the lab; bremelanotide is its International Nonproprietary Name. Papers and catalogues use both, sometimes in one sentence, and both point to C50H68N14O10, CAS 189691-06-3.

    It belongs to the melanocortin peptide family, built around a short stretch of alpha-melanocyte-stimulating hormone. The family shares a four-residue core, His-Phe-Arg-Trp, that the receptors recognise, and PT-141 carries it inside the ring.

    The ring is the point. A straight peptide chain is floppy: it wanders through hundreds of shapes a second, and only a few of those fit a receptor. Tie two side chains together, and it can no longer flop. That’s what “cyclic” means here.

    PT-141 Structure: The Ring, the Residues and the Ends

    PT-141 bremelanotide structure diagram

    PT-141 bremelanotide structure

    The Asp2–Lys7 Lactam Bridge

    The bond that closes the ring is a lactam, chemistry’s word for an amide bond formed inside a molecule. The side-chain carboxyl of aspartic acid at position 2 joins the side-chain amine on the end of lysine at position 7, which PubChem writes as a “(2→7)-lactam”.

    Count the atoms going round, and you get 23, so it’s a 23-membered macrocycle. That comes straight off the PubChem record for CID 9941379, whose IUPAC name ends in “hexazacyclotricosane-23-carboxylic acid”. Tricosane means 23.

    Norleucine, D-Phe and the His-Phe-Arg-Trp Core

    Two residues are swapped out from what you’d expect in a natural peptide, and both swaps are deliberate.

    Norleucine takes position 1, where the parent hormone has methionine. The two are near twins, except norleucine has a plain carbon chain where methionine has a sulfur atom. Sulfur oxidises, so removing it leaves one less way for the molecule to go off in storage and one less stray peak on a chromatogram.

    Position 4 is D-phenylalanine. Amino acids come in left-handed and right-handed versions, and biology almost always uses the left-handed (L) form. This one is the mirror image, and it falls midway through the His-Phe-Arg-Trp stretch at positions 3 to 6.

    The N-Acetyl Cap and the C-Terminal Free Acid

    Both ends are modified. The N-terminus carries an acetyl group, a small cap that blocks the free amine, and the other end finishes as a carboxylic acid, written -OH.

    That second detail is easy to skim past and worth slowing down for. Plenty of research peptides end in an amide (-NH2) instead, and the choice changes the formula, the mass, and which molecule you have.

    PT-141 and Melanotan II: One Structural Difference

    Same seven residues, same ring, closed the same way in the same place. The two diverge at one spot: the C-terminus.

    PT-141Melanotan II
    C-terminusFree acid, -OHAmide, -NH2
    FormulaC50H68N14O10C50H69N15O9
    Average MW1025.21024.2 g/mol

    The team behind the MC4R cryo-EM structures put it in three words, calling bremelanotide “C-terminal OH-MT-II” in Cell Research. One nitrogen traded for one oxygen, about 1 g/mol apart. Keep the Melanotan II structure and sequence beside this one if you run both: a single mass near 1024 to 1025 cannot separate them on a low-resolution instrument.

    What Is the PT-141 Sequence?

    Quick answer: PT-141’s sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, seven residues. A lactam bond between the Asp2 side chain and the Lys7 side chain closes the ring, and the N-terminus is acetylated. The one-letter form is Ac-[Nle]-c[DH(f)RWK]-OH, where lowercase f marks D-phenylalanine.

    Read that line left to right, and it gives you the chain, the odd residue out, and where the ring starts and stops. Square brackets flag a residue with no standard one-letter code, and lowercase f is the convention for a D-amino acid.

    PositionResidueConfigurationNotes
    1Norleucine (Nle)LOutside the ring; carries the acetyl cap
    2Aspartic acid (Asp)LSide-chain carboxyl forms the lactam
    3Histidine (His)LStarts the His-Phe-Arg-Trp core
    4Phenylalanine (Phe)DThe single D-configuration residue
    5Arginine (Arg)LCore; main basic site
    6Tryptophan (Trp)LCore; absorbs the UV HPLC reads
    7Lysine (Lys)LSide-chain amine closes the ring; free-acid C-terminus

    These are PT-141’s own positions, 1 through 7. Older melanocortin papers number the same residues by where they fell in the parent hormone, which is why the literature gives Asp5 and Lys10 for the same bond in related analogues.

    What Is PT-141’s Molecular Weight?

    Quick answer: PT-141 (bremelanotide) has an average molecular weight of 1025.2 g/mol and a monoisotopic mass of 1024.52 Da (formula C50H68N14O10, PubChem CID 9941379). Research material is often an acetate salt, which has its own CAS and a higher weight per mole, so net peptide content is reported separately.

    Most mismatches people worry about come down to which of the two numbers a report picked. 1025.2 g/mol is the average mass, every atom weighed by how common its isotopes are, and it’s the number to use at the balance. 1024.52 Da is the monoisotopic mass, counting only the lightest common isotope of each element, and that’s what a spectrometer reads. Compare a measurement against the wrong one and a clean sample looks off.

    Then there’s the salt. As the acetate, PT-141 becomes CAS 1607799-13-2, formula C52H72N14O12, and the weight climbs to 1085.2 g/mol. Those 60 extra grams per mole are acetate, so the peptide is roughly 94% of that salt before bound water. Hence the separate net-peptide-content line on a good certificate.

    Here’s what the ions look like, with real numbers from a tested batch:

    IonExpectedMeasured, Life Link batch
    [M+2H]²⁺513.3513.271
    [M+H]⁺1025.51025.529

    Those come from the MZ Biolabs certificate for PT-141 lot 2024-09-03, analysed on 8 October 2024 by analytical chemist Ken Pendarvis: expected monoisotopic mass 1024.52 Da against a measured 1024.53 Da. The doubly charged ion is the taller peak, normal for a peptide this size.

    Which Receptors Does PT-141 Bind?

    Quick answer: PT-141 is studied as an agonist at melanocortin receptors, with most data at MC4R and MC3R. In vitro work measures its activity with cAMP accumulation and radioligand-binding assays. A 2021 cryo-EM structure (PDB 7F55, Cell Research) shows bremelanotide bound to MC4R in complex with the Gs protein.

    Melanocortin receptors are G protein-coupled receptors, and the standard way to read activity at them is cAMP. The receptor couples to Gs, Gs switches on adenylyl cyclase, cAMP rises inside the cell, and a plate reader picks up the change. Radioligand binding runs alongside it, measuring how well the compound displaces a labelled tracer in HEK293 or CHO cells carrying one human subtype. Binding tells you how tightly it grips; cAMP tells you what the receptor does next.

    What the 7F55 Structure Shows

    PDB entry 7F55 is the bremelanotide–MC4R–Gs–Nb35 complex, solved by cryo-electron microscopy at 3.1 Å and released on 3 November 2021, from work by Hui Zhang and colleagues at Zhejiang University and the Shanghai Institute of Materia Medica published in Cell Research (PMID 34433901).

    The surprise was an extra passenger in the pocket. A divalent calcium ion is lodged in the binding site alongside the peptide, and the authors describe it as “considered a necessary cofactor for ligand binding and activity”. Strip calcium out with EGTA and bremelanotide stops producing cAMP. Mutating receptor residue D126 abolishes the response; mutating E100 cuts potency about twentyfold.

    Inside the pocket, the His-Phe-Arg-Trp core does the recognising, as it does for every peptide in this family. The D-Phe of bremelanotide “almost stayed at the same position” as the equivalent residue in alpha-MSH, which is the structural reason the mirror-image swap works. Professor Zhang Yan of Zhejiang University, who led the work, said the results “offer unprecedented structural insights into the pharmacological and signaling features of MC4R” (university announcement, 2 October 2021).

    How to Read a PT-141 COA

    Quick answer: A PT-141 COA should show RP-HPLC purity for that batch with its chromatogram, ESI-MS identity matching 1025.2 Da, net peptide content, the salt form, lot number, test date, and testing lab. Report purity as the batch result. Check that the lot on the COA matches your vial.

    What to checkWhat it should show
    HPLC purityThe batch result, with its chromatogram
    MS identity[M+H]⁺ about 1025.5 and/or [M+2H]²⁺ about 513.3
    Salt formFree base or acetate, stated
    Net peptide contentStated separately from purity
    AppearanceWhite lyophilized powder
    Lot numberMatches the vial label
    Lab name and datePresent, checkable

    Purity and identity answer different questions, and you need both. HPLC purity is the share of UV-absorbing material under the main peak, read at 210 to 220 nm, so it tells you how clean the sample is. What the main peak actually is comes from the mass spectrometer, which for this compound is looking at 1025.5 or 513.3.

    Net peptide content is the line most certificates leave off. A vial labelled 10 mg carries peptide plus counterion plus whatever water the powder picked up, so the net figure is what tells a lab how much PT-141 it’s weighing. Life Link’s current PT-141 certificate, from Prime Analytical Laboratories on 19 March 2026 under report RP218-16Mar26-8, gives 99.78% purity at 210.4 nm and 11.53 mg net peptide content. That report lists the sample lot number as “Not Provided”, which shows what the lot line is for: a certificate with no lot can be attached to any batch, so ask for one carrying the code printed on your vial.

    A few independent services now re-test vials and publish what they find, a useful cross-check when a certificate looks too tidy. What they flag most often is ordinary: round purity numbers with no chromatogram, identical reports across lots, a blank testing-lab field. Learning how to verify a peptide COA end to end makes those quick to spot. Identity and purity run on every batch under our third-party testing, with heavy metals, endotoxin, and sterility on a rotating cycle across the catalogue. PT-141 is soluble in water/DMSO for assay preparation, and the lyophilized powder is stored at -20 °C, dry, dark, and sealed.

    Is PT-141 the Same as Bremelanotide?

    Quick answer: Yes. PT-141 is the development code, and bremelanotide is the International Nonproprietary Name for the same molecule, C50H68N14O10, CAS 189691-06-3. Research-grade PT-141 from chemical suppliers is sold as a laboratory reagent for research use only. It is not a pharmaceutical product and is not intended for human use.

    Matching a catalogue listing against a paper, the identifiers settle it faster than the names. CAS 189691-06-3, PubChem CID 9941379, and FDA UNII 6Y24O4F92S all resolve to the same structure, whichever name is on the label. A UNII is an identity code and carries no approval.

    The material a chemical supplier ships under either name is a laboratory reagent for in vitro research by qualified professionals.

    PT-141 FAQ

    How many amino acids are in PT-141?

    Seven: Nle, Asp, His, D-Phe, Arg, Trp, and Lys. Six of them are inside the ring, with the norleucine hanging off the outside under its acetyl cap.

    Is PT-141 a cyclic peptide?

    Yes. A lactam bond between the Asp2 and Lys7 side chains closes a 23-membered ring. PubChem records this as a “(2→7)-lactam”, and the ring size shows up in the systematic name as “cyclotricosane”.

    What is the CAS number for PT-141?

    189691-06-3 for the free base. The acetate salt has its own number, 1607799-13-2, formula C52H72N14O12, average weight 1085.2 g/mol. Check which form a certificate means before any weight calculation.

    How should lyophilized PT-141 be stored?

    Keep the vial at -20 °C, dry, dark, and sealed, with a desiccant if you have one. Bring it to room temperature before opening so moisture doesn’t condense on cold powder. Tryptophan absorbs UV, so amber glass or a closed box earns its keep.

    Is PT-141 soluble in water?

    PT-141 is soluble in water/DMSO for assay preparation. The arginine and histidine give the molecule charged sites that water interacts with well.

    Working With PT-141 in the Lab

    Four checks cover most of what can go wrong: a chromatogram behind the purity figure, a mass reading near 1025.5 or 513.3, a lot code matching the label, and a named testing lab you can contact.

    Life Link publishes the current certificate on each product page, so you can read the lab, the date, and the chromatogram before ordering: open the product and click “COA verified – View report”. Specifications and the batch report for the PT-141 10mg research vial are published together, tested by Janoshik Analytical or a US lab.

    For Research Use Only. Not for use in diagnostic or therapeutic procedures. Life Link Research supplies PT-141 to qualified laboratories for in vitro study only.

  • What Is Cagrilintide? Structure, Sequence & COA

    What Is Cagrilintide? Structure, Sequence & COA

    Quick Answer

    Cagrilintide is a synthetic amylin analog developed by Novo Nordisk under the code AM833. If you have a vial on the bench and a certificate open in another tab, the chemistry is what you need: what the molecule is built from, what the numbers on the label should read, and whether the paperwork matches.

    That is what this page covers: the 37-residue sequence in one-letter and three-letter form, the six substitutions that separate cagrilintide from human amylin, the fatty chain on the N-terminus, both molecular weights, the receptors it has been studied at, and a line-by-line way to read a batch COA. Chemistry only.

    Everything below describes laboratory material supplied under the research disclaimer that governs every product on this site.

    FieldValue
    Name and synonymsCagrilintide; AM833; NN0174-0833
    ClassLipidated amylin analog
    Residues37
    Molecular formulaC194H312N54O59S2
    Molecular weight4409.0 g/mol average; 4406.25 Da monoisotopic
    CAS number1415456-99-3
    UNIIAO43BIF1U8
    PubChem CID171397054
    ModificationsN-terminal C20 diacid on a γ-glutamate linker; Cys2-Cys7 disulfide; C-terminal amide
    Receptors studiedCalcitonin receptor (CTR); AMY1, AMY2, AMY3

    Formula, weight, CAS, and CID from PubChem CID 171397054; precisionFDA records UNII AO43BIF1U8 under the name “cagrilintide”.

    What Is Cagrilintide?

    Quick answer: Cagrilintide is a synthetic peptide analog of human amylin, a 37-residue hormone. It carries a C20 fatty diacid on a γ-glutamate linker at the N-terminus and keeps amylin’s Cys2-Cys7 disulfide ring. Novo Nordisk developed it under the code AM833. In research, it is studied as an agonist at amylin and calcitonin receptors.

    Amylin is the parent molecule here, a 37-amino-acid hormone the pancreas releases alongside insulin, which binds a small receptor family built around the calcitonin receptor.

    Two words do the heavy lifting. An analog is a peptide rebuilt from a natural sequence with deliberate swaps, keeping the shape that fits the receptor while behaving better as a laboratory compound. Lipidated means a fatty acid chain has been attached, a standard way of making a peptide stick to proteins in blood.

    Both choices are documented. The design work was published by Thomas Kruse and colleagues at Novo Nordisk as “Development of Cagrilintide, a Long-Acting Amylin Analogue” in the Journal of Medicinal Chemistry, 2021, volume 64, pages 11183 to 11194. That paper is the primary reference for the next three sections, and the team is blunt about the problem they were solving: human amylin’s habit of clumping into fibrils made it, in their words, “a challenging drug design effort”.

    Cagrilintide Structure: The Four Parts of the Molecule

    Cagrilintide is a 37-residue peptide chain carrying three modifications: a disulfide ring near the N-terminus, a C20 fatty diacid on a γ-glutamate linker at position 1, and an amide cap at the C-terminus. Take them one at a time, and the molecule is easy to keep in your head.

    Cagrilintide structure diagram

    The four structural parts of cagrilintide, with the Cys2-Cys7 ring, the C20 diacid chain and the C-terminal proline amide marked on the 37-residue backbone.

    The 37-residue peptide backbone

    The backbone runs 37 amino acids, the same length as human amylin, counted from the N-terminal lysine at position 1 to the proline at position 37. Keep that numbering straight, because the chemical naming in some databases counts the γ-glutamate linker as part of the chain and moves every number by two. Stick to peptide numbering and Cys2, Glu14, Arg17, and Pro37 land where the literature puts them.

    The Cys2-Cys7 disulfide ring

    A disulfide bond joins the cysteines at positions 2 and 7, closing a six-residue loop at the front of the molecule. Human amylin carries the same ring, kept unchanged in cagrilintide. PubChem’s systematic name calls it a “cyclic (3→8)” bridge, which looks wrong until you notice the database counts the γGlu linker as residue 1. Same bond, different starting point.

    The N-terminal C20 diacid and γGlu chain

    The long chain at the front is eicosanedioic acid, a 20-carbon fatty acid with a carboxyl group at both ends, joined through a γ-glutamate linker to the α-amine of Lys1. Kruse and colleagues chose that chain to make the molecule bind albumin, the most abundant protein in blood. Albumin binding is a chemical design feature of the lipid, and this article makes no claim about what it does in an organism.

    Only part of that chain shows up in structural work. In the 2025 cryo-EM maps, the γGlu linker and a short stretch of the diacid could be modelled, and the rest stayed unresolved, which is normal for a flexible lipid tail.

    The C-terminal proline amide

    The chain ends in a proline amide, written Pro37-NH2, where human amylin ends in an amidated tyrosine. That swap is well tolerated and raises affinity and activity at both the calcitonin receptor and the amylin receptors, as the 2025 structural work describes.

    What Is the Cagrilintide Amino Acid Sequence?

    Quick answer: Cagrilintide’s sequence is KCNTATCATQRLAEFLRHSSNNFGPILPPTNVGSNTP-NH2, 37 residues. A C20 diacid and γGlu chain are attached at the N-terminal lysine, and a disulfide links Cys2 and Cys7. Compared with human amylin, it carries six substitutions: N14E, V17R, A25P, S28P, S29P, and Y37P.

    One-letter:

    KCNTATCATQRLAEFLRHSSNNFGPILPPTNVGSNTP-NH2

    Three-letter:

    Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Glu-Phe-
    Leu-Arg-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-
    Asn-Val-Gly-Ser-Asn-Thr-Pro-NH2
    PositionHuman amylinCagrilintideWhy it was changed
    14Asn (N)Glu (E)Pairs with Arg17 in a salt bridge that stabilises the N-terminal helix and counters fibril formation
    17Val (V)Arg (R)The second half of that salt bridge, same helix-stabilising job
    25Ala (A)Pro (P)Carried over from pramlintide, the backbone peptide cagrilintide was built on
    28Ser (S)Pro (P)Same pramlintide backbone; prolines here break up the stretch that drives aggregation
    29Ser (S)Pro (P)Same pramlintide backbone
    37Tyr (Y)Pro (P)Amidated proline raises affinity and activity at CTR and the amylin receptors

    The N14E and V17R pair is the interesting one. Writing in Nature Communications in April 2025, Jianjun Cao and colleagues at Monash University describe them as a pair of helix-stabilising mutations put in to counteract the amyloid fibril formation that happens with human amylin, forming an internal salt bridge that holds the 5 to 18 helix together.

    Two wrong numbers circulate. Some catalogue listings give the length as 39 amino acids, and at least one AI-generated summary inserts an extra proline into the C-terminal run. The chain is 37 residues plus the lipid chain; count the string above to settle it.

    What Is Cagrilintide’s Molecular Weight?

    Quick answer: Cagrilintide’s average molecular weight is 4409.0 g/mol, from the formula C194H312N54O59S2 on PubChem. Its monoisotopic mass is 4406.25 Da. Lyophilized research material is usually supplied as a salt, such as acetate or TFA, so the mass in the vial includes counter-ions. A COA reports net peptide content separately from HPLC purity.

    The two weights answer different questions. Average molecular weight (4409.0) sums the average mass of every element across its natural isotopes, and it is the figure for weighing out material. Monoisotopic mass (4406.25) uses only the lightest isotope of each element, and it is what a mass spectrometer works from.

    One trap is in the PubChem record itself. Its “exact mass” field reads 4408.26, about two hydrogens above the monoisotopic value, so a certificate quoting 4406.25 is correct and matches a hand calculation from the formula.

    Salt form changes the weight per milligram. A vial labelled 5 mg of a TFA or acetate salt contains less than 5 mg of peptide, because the counter-ions carry part of that mass. Net peptide content is the line that tells you how much.

    Vendor pages are not a safe source for any of this. A scan of catalogue listings turns up masses of roughly 3950, 4030, 4052 and 4578 Da for the same compound, none matching the published formula. Take the weight from PubChem or recalculate it from the sequence.

    Which Receptors Does Cagrilintide Bind?

    Quick answer: Cagrilintide is studied as an agonist at the calcitonin receptor (CTR) and at the three amylin receptors, AMY1, AMY2, and AMY3. Each amylin receptor is a calcitonin receptor paired with RAMP1, 2 or 3. In vitro work measures its activity with cAMP accumulation and radioligand-binding assays, and cryo-EM has resolved its receptor-bound structures.

    The RAMP part makes this family unusual. A receptor activity-modifying protein is a small accessory protein that pairs with the calcitonin receptor and changes what it prefers to bind. CTR with RAMP1 gives AMY1; with RAMP2, AMY2; with RAMP3, AMY3. The receptor gene is the same in all three.

    Cagrilintide has been resolved at all four. Cao and colleagues determined cryo-EM structures of the peptide bound to Gs-coupled, active AMY1, AMY2, AMY3 and CTR, and reported that it takes up an amylin-like binding mode while inducing “distinct conformational dynamics at calcitonin-family receptors” compared with other peptides. Patrick Sexton, professor of pharmacology at Monash University, is the senior author on that work.

    Two assay terms come up constantly. cAMP accumulation measures the second messenger these receptors raise when activated. Radioligand binding measures how tightly a compound binds the receptor by competing against a labelled reference peptide. Both appear in the Kruse paper, alongside structure-activity work at human CTR and AMY3.

    Is cagrilintide a GLP-1 receptor agonist?

    No. Cagrilintide is an amylin analog, and the receptors it has been characterised at are the calcitonin receptor and the amylin receptors AMY1 to AMY3. The GLP-1 receptor is a separate incretin receptor with its own ligands. The confusion comes from blend products that pair cagrilintide with a GLP-1 compound in one vial.

    How to Read a Cagrilintide COA

    A cagrilintide COA should show RP-HPLC purity for that batch, ESI-MS identity matching 4409.0 Da, net peptide content, lot number, test date, and the testing lab. Purity is whatever the batch result shows, so read the chromatogram instead of a headline figure. The MS peaks should match cagrilintide’s expected charge states.

    What to checkWhat it should show
    HPLC purityThe batch result with its chromatogram attached, and the peak labelled
    MS identityCharge states near [M+3H]³⁺ 1470.7, [M+4H]⁴⁺ 1103.3 and [M+5H]⁵⁺ 882.8, calculated from the 4409.0 average; recalculate against the actual report
    Net peptide contentStated as its own line, separate from purity
    AppearanceWhite lyophilized powder
    Lot numberPresent, and matching the vial label
    Lab name and dateBoth present, and checkable with the lab

    Those charge states are arithmetic. Add three protons to 4409.0, divide by three, and you get 1470.7. A report whose peaks land somewhere else is describing a different molecule. Appearance is the quick sanity check: a white lyophilized powder, and the material itself is soluble in water/DMSO for assay preparation.

    Lot number is the field that most often lets a certificate down. The cagrilintide 5mg research vial we sell carries a Prime Analytical report, RP218-17Apr26-1 dated 22 April 2026, giving 100.00% purity at 220 nm and net peptide content of 5.52 mg, with a sample lot field reading “Not Provided”. An earlier Janoshik report, task #68672 from 24 June 2025, gives 99.148% and 5.29 mg. Neither includes a mass-spec run, so identity is not something you can read off them. Third-party testing covers identity and purity on every batch, with heavy metals, endotoxin, and sterility on a rotating cycle.

    Finnrick, which publishes buyer-submitted lab results, lists 200 cagrilintide tests between 20 April 2025 and 2 November 2026: 107 passed and 91 failed against a bar of 99.5% purity and dose within 35% of label. Checking the reference number with the lab itself is the first move when you verify a peptide COA.

    Cagrilintide in Two-Peptide Research Blends

    Cagrilintide is also supplied in two-peptide vials, paired with a second compound in a single lyophilized cake. The certificate then has twice as much work to do.

    The cagrilintide-GLP-3 RT blend chemistry in the first of those pairs: two molecules roughly 320 Da apart in weight that bind unrelated receptor families.

    A two-peptide COA has to resolve both compounds: two separated peaks on the HPLC chromatogram, each labelled and each with its own area, plus two mass identities. An amount per compound should appear too, since the label states a quantity for each. A single purity figure on a two-peptide vial is not a result you can work with, which is the practical argument for weighing blends vs single vials by how much the certificate can prove.

    Is Cagrilintide FDA Approved?

    Quick answer: As of 14 November 2026, cagrilintide is not approved by the FDA as a standalone drug. It remains an investigational compound, and the agency’s Drugs@FDA database returns no approved product under that name. A combination application naming cagrilintide as one of two active ingredients was submitted by Novo Nordisk in December 2025, and no approval decision has been announced.

    Material sold by research suppliers, including everything on this site, is for laboratory research use only and not for human use.

    Cagrilintide FAQ

    How many amino acids are in cagrilintide?

    Cagrilintide has 37 amino acids, the same chain length as human amylin, plus a C20 fatty diacid attached through a γ-glutamate linker at the N-terminal lysine. Catalogue listings that give 39 residues are counting the linker as part of the chain. The peptide sequence itself runs from Lys1 to Pro37.

    Who developed cagrilintide?

    Novo Nordisk developed cagrilintide, and its chemists published the design work in the Journal of Medicinal Chemistry in 2021. It appears in the literature and in supplier catalogues under two internal codes, AM833 and NN0174-0833. Both names refer to the same molecule, CAS 1415456-99-3.

    Is cagrilintide the same as amylin?

    No. Cagrilintide is built from the amylin template but differs in three ways: six residue substitutions (N14E, V17R, A25P, S28P, S29P and Y37P), a C20 fatty diacid chain at the N-terminus, and a proline amide at position 37 in place of amylin’s amidated tyrosine. The Cys2-Cys7 disulfide ring is the same in both.

    How should lyophilized cagrilintide be stored?

    Store the sealed vial of lyophilized powder at -20 °C, kept dry and shielded from light. Leave it sealed until needed, since repeated exposure to room air brings in moisture. These conditions apply to the dry powder as supplied and to nothing else.

    What is cagrilintide’s CAS number?

    Cagrilintide’s CAS registry number is 1415456-99-3, and its FDA Unique Ingredient Identifier is AO43BIF1U8. The PubChem compound ID is 171397054. Any of the three will pull up the same substance record, a quick way to check a supplier’s paperwork describes the molecule it claims to.

    Working with Cagrilintide in the Lab

    Four numbers from this page are the ones worth keeping next to the bench: 37 residues, formula C194H312N54O59S2, 4409.0 g/mol average and 4406.25 Da monoisotopic. Check those against any certificate before the vial goes near an assay, and check that the lot on the paper matches the lot on the glass.

    For single-compound work, a 5 mg vial with its own batch certificate is the cleaner start: one peptide, one peak, one mass to confirm. The two-peptide blends suit a protocol that calls for both compounds in one preparation, and they ask more of the paperwork.

    For Research Use Only. Not for use in diagnostic or therapeutic procedures. These products are laboratory reagents for in-vitro research by qualified professionals aged 21 and over, have not been evaluated or approved by the U.S. Food and Drug Administration, and nothing on this page is medical advice.

  • What Is Tesamorelin? Structure, Sequence, and COA Guide

    What Is Tesamorelin? Structure, Sequence, and COA Guide

    Quick Answer

    Tesamorelin is a synthetic 44-amino-acid analog of human GHRH(1-44), carrying a trans-3-hexenoyl group on the nitrogen end of its first residue. Everything after that cap is the natural hormone sequence, residue for residue. One small acyl group is the entire design change, and it is the reason the molecule behaves the way it does in a protease assay.

    This guide covers what a buyer checks before a vial goes into an experiment: the 44-residue backbone and the record it comes from, the acyl cap and the C-terminal amide, the registry identifiers and where they disagree, free base against acetate salt, the GHRH-receptor assays, and what a batch certificate should show.

    For Research Use Only. Not for use in diagnostic or therapeutic procedures.

    What Is Tesamorelin?

    Quick answer: Tesamorelin is a 44-residue analog of GHRH(1-44) developed under the code TH9507, built with an N-terminal trans-3-hexenoyl group and a C-terminal amide. Its molecular formula is C221H366N72O67S and its average molecular weight is 5135.9 Da, under CAS 218949-48-5. Laboratories work with it as a ligand at the GHRH receptor.

    Tesamorelin belongs to the growth-hormone-releasing hormone analog class, the family of peptides built on the hypothalamic GHRH sequence. Within that family, it sits at the long end. Sermorelin and modified GRF(1-29) use the first 29 residues; tesamorelin carries all 44.

    Tesamorelin still appears under its development code, TH9507, in older literature and on supplier labels. A second registry number, 804475-66-9, resolves to the same PubChem record, CID 16137828, so a certificate quoting it has not quoted the wrong compound.

    Tesamorelin and native GHRH(1-44) differ at one position only, and it is not a residue. The 44 amino acids are identical. The change is a six-carbon acyl group bolted to the amino terminus, which leaves the backbone sequence untouched and alters only how the N-terminal end presents itself to enzymes.

    Tesamorelin Structure: What Does It Consist Of?

    Quick answer: Tesamorelin consists of three structural parts: a 44-residue peptide chain matching human GHRH(1-44), a trans-3-hexenoyl acyl cap on the alpha-amino group of Tyr1, and an amide at the C-terminal leucine. The chain supplies the receptor-binding surface. The cap and the amide sit at the two ends, where they change the molecule’s chemistry.

    The 44-Residue GHRH Backbone

    Tesamorelin uses the human GHRH(1-44) sequence without substitution. In UniProt, that chain is a defined feature of the somatoliberin precursor: entry P01286 runs 108 amino acids, and residues 32 to 75 are annotated as the mature peptide. Those 44 residues read YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL.

    Pull the sequence from that chain feature rather than from a free-text field, because free-text copies circulate with an error in them.

    The Trans-3-Hexenoyl Cap on Tyr1

    Tesamorelin carries an (E)-hex-3-enoyl group, a straight six-carbon acyl chain with a double bond in the trans configuration between carbons 3 and 4, joined through an amide bond to the alpha-amino nitrogen of Tyr1.

    Capping that nitrogen has a specific chemical consequence. Dipeptidyl peptidase-IV recognises a free N-terminal amine followed by a small residue at position 2, and native GHRH presents exactly that pattern. Frohman, Downs, Heimer and Felix characterised the reaction in human plasma in vitro and reported in the Journal of Clinical Investigation in 1989 that the enzyme cuts the Ala2-Asp3 bond, carrying off the Tyr1-Ala2 dipeptide and leaving GRH(3-44)-NH2. Diprotin A, a competitive DPP-IV inhibitor, blocked the conversion, and a D-amino acid at position 1 or 2 prevented hydrolysis altogether.

    An acyl group on Tyr1 removes the free amine the enzyme needs. In enzymatic stability work in vitro, that is the function the cap performs.

    The C-Terminal Amide

    Tesamorelin terminates in Leu44-NH2. Amidation replaces the hydroxyl of the terminal carboxylic acid with an amino group, so the peptide ends in a neutral amide instead of a negatively charged carboxylate.

    Two things follow. The formula gains an NH and loses an O relative to the free acid, which shifts the mass by roughly one unit. And the C-terminus stops carrying a negative charge at neutral pH, which is worth knowing when interpreting a charge-state envelope on a mass spectrum.

    What Is the Tesamorelin Sequence?

    Quick answer: The tesamorelin sequence is (E)-hex-3-enoyl-YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL-NH2: 44 amino acids in the one-letter code, an acyl cap at the front and an amide at the back. Written out, it runs from Tyr1 through Leu44, with valine at position 13 and a single methionine at position 27.

    PositionsOne-letterResidues
    1 to 10YADAIFTNSYTyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr
    11 to 20RKVLGQLSARArg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg
    21 to 30KLLQDIMSRQLys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln
    31 to 40QGESNQERGAGln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala
    41 to 44RARLArg-Ala-Arg-Leu

    Position 1 carries the trans-3-hexenoyl cap. Position 44 carries the amide.

    Tesamorelin's 44 residues in blocks of ten with Val13 highlighted, beside the calculated and observed electrospray charge-state ladder

    Tesamorelin’s 44 residues in blocks of ten with Val13 highlighted, beside the calculated and observed electrospray charge-state ladder

    Composition is as useful a check as the string itself. The chain carries six arginines and two lysines, which makes it strongly basic, and exactly one methionine, at position 27. That single methionine is why the molecular formula ends in a lone sulfur atom, so any sequence offering two methionines is describing something else.

    Some databases print this sequence with only 43 residues. The KEGG drug record D06655 is the clearest example: its SEQUENCE field runs Arg-Lys straight into Leu-Gly, skipping Val13 entirely. The same record’s FORMULA field reads C221H366N72O67S and its MOL_WEIGHT reads 5135.78, and both of those are the 44-residue values, so the record disagrees with itself. Two checks catch this in seconds. Count the residues, and confirm that valine sits at position 13 between Lys12 and Leu14. The 44-residue version is the one that produces the published formula and the published mass, and a 43-residue copy will quietly fail both.

    Tesamorelin Chemical Data at a Glance

    FieldValue
    CAS (free base)218949-48-5
    PubChem CID16137828
    UNIIMQG94M5EEO
    Molecular formulaC221H366N72O67S
    Average molecular weight5135.9 Da
    Monoisotopic mass5132.72 Da
    Length44 amino acids
    Development codeTH9507
    Acetate formC221H366N72O67S·xC2H4O2, x ≈ 7
    Acetate CAS901758-09-6

    Small differences between sources are a matter of rounding. Calculated from standard atomic weights, the average mass of C221H366N72O67S is 5135.86. KEGG lists 5135.78, PubChem lists 5136, and the manufacturer’s product description rounds to 5135.9. All four describe the same molecule.

    The monoisotopic figure deserves its own note, because a commonly copied value is wrong. Calculated from the formula, the monoisotopic mass is 5132.72 Da, which matches KEGG’s EXACT_MASS field and PubChem’s MonoisotopicMass field. PubChem’s separate ExactMass field on that record reads 5134.72, about 2 Da high, and that is the number that tends to get repeated. Use 5132.72.

    The acetate registry number carries a caveat of its own. CAS 901758-09-6 is attached to the USAN name tesamorelin acetate in the KEGG record D09015, alongside the formula C221H366N72O67S·(C2H4O2)x. PubChem returns no compound under that number, so a search there will come back empty even though the number is real.

    Tesamorelin Free Base vs Acetate Salt

    Tesamorelin is supplied as an acetate salt. The manufacturer’s product description gives the salt formula as C221H366N72O67S·xC2H4O2 with x approximately 7, and the molecular weight 5135.9 Da as free base equivalent. Those seven acetate counter-ions are part of what sits in the vial, and they are not peptide.

    Acetate is the standard counter-ion for synthetic peptides because basic side chains need something to pair with after purification. Tesamorelin has eight basic residues: six arginines at positions 11, 20, 29, 38, 41 and 43, plus lysines at 12 and 21. Seven acetates for eight basic sites is the stoichiometry the composition predicts.

    The arithmetic matters when reading a certificate. Seven acetates add 420.4 Da to 5135.9, giving a gross salt mass near 5556, so the free base accounts for roughly 92 percent of the salt’s weight. The manufacturer’s own figures say the same thing in a different unit: a presentation stated as 2 mg of tesamorelin is described as approximately 2.2 mg of tesamorelin acetate.

    Gross vial weight therefore overstates peptide, and that gap is a live question in analytical chemistry. Nassim Maarouf-Mesli and Charity D. Yongo-Luwawa, in William Lubell’s group at the Université de Montréal, published a 2026 NMR method written up by the American Peptide Society that fixes peptide quantity to a proton signal integration instead of a balance reading. Their method targets trifluoroacetate, and the premise carries across to acetate salts: what you weigh and what you weighed are two different numbers.

    How Does Tesamorelin Interact With the GHRH Receptor?

    Quick answer: Tesamorelin acts as an agonist at the GHRH receptor, GHRHR, a class B G-protein-coupled receptor that couples to Gs and signals through cyclic AMP. In cell-based work, the readouts are cAMP accumulation in lines expressing recombinant GHRHR, and competition against a labelled ligand in radioligand binding assays.

    Tesamorelin studies in this area run in two assay formats. Cyclic AMP accumulation assays measure second-messenger output in transfected cells across a concentration range, and radioligand binding assays measure displacement of a labelled GHRH analog from membrane preparations.

    Tesamorelin’s target has been resolved structurally. Zhou and colleagues reported a cryo-EM structure of the human GHRHR in complex with Gs at 2.6 Angstrom resolution in Nature Communications in 2020, deposited as PDB entry 7CZ5 and reconstructed from 307,018 particles. They describe GHRHR as “a prototypical class B GPCR” signalling “through cyclic adenosine monophosphate (cAMP)-dependent pathways”, and report that GHRH “adopts an α-helical configuration when engaged with GHRHR”.

    Receptor identity separates GHRH analogs from the other secretagogue family cleanly, because GHRHR and GHSR-1a take different ligands. Ipamorelin acts at GHSR-1a, a receptor tesamorelin has no affinity for.

    Tesamorelin vs Sermorelin: Structural Differences

    Tesamorelin and sermorelin are both GHRH analogs built on the same natural sequence, and they differ in length and in end-group chemistry. Sermorelin is GHRH(1-29)-NH2, the 29-residue N-terminal fragment with a free amino terminus. Tesamorelin carries the full 44 residues and an acyl cap on Tyr1.

    FeatureTesamorelinSermorelin
    Length44 aa29 aa
    N-terminustrans-3-hexenoylFree
    C-terminusAmideAmide
    FormulaC221H366N72O67SC149H246N44O42S
    Average MW5135.9 Da3357.9 Da
    Monoisotopic mass5132.72 Da3355.82 Da
    CAS218949-48-586168-78-7
    PubChem CID1613782816132413

    Sermorelin’s figures come from PubChem CID 16132413. The 1778 Da gap between the two average masses is simply residues 30 to 44 plus the acyl cap, and it is large enough that no mass spectrometer should ever confuse the two.

    The structural contrast is sharpest at the N-terminus. Sermorelin’s amino terminus is free, which leaves the DPP-IV pattern intact; tesamorelin’s is acylated. That single difference is why the two behave differently in plasma-stability assays despite sharing their first 29 residues exactly.

    A third analog rounds out the family. Modified GRF(1-29) builds on the same 29-residue fragment with four amino acid substitutions, and the question of CJC-1295 with vs without DAC turns on whether a maleimidopropionyl group is attached for albumin conjugation. Comparing the three side by side is the fastest way to see how much of GHRH analog chemistry happens at the two ends of the chain. Sermorelin also anchors a comparison that crosses receptor families, and ipamorelin vs sermorelin sets a GHRH analog against a ghrelin-receptor ligand whose only shared feature is the C-terminal amide.

    How to Read a Tesamorelin COA

    A tesamorelin certificate of analysis should show four things: an HPLC chromatogram with that batch’s own purity percentage, a mass spectrum confirming identity near 5135.9 Da average, the lot or batch identifier matching the vial, and the name and date of the laboratory that ran the tests. Anything missing from that list is a gap worth asking about.

    HPLC Purity

    Purity on a tesamorelin COA is a reverse-phase HPLC result for one specific batch, usually read at 214 or 220 nm. Report the batch’s own figure and check the retention time and the chromatogram alongside it, because a single sharp peak tells you more than a number on its own.

    We pulled the current certificate for our 10 mg vial before writing this. Bioviridian ran it at 214 nm and reported 99.82 percent overall purity, retention time 10.412 minutes, on a sample received 31 August 2026. That figure belongs to that batch, so read the batch result for the lot you receive. Learning how to verify a peptide COA starts with the number attached to the material in your hand.

    Mass-Spec Identity

    Identity confirmation on a tesamorelin COA comes from electrospray mass spectrometry, which rarely gives one peak at 5135.9. Large peptides pick up several protons and appear as a ladder of multiply charged ions, each at the molecular mass divided by its charge. Calculated from an average mass of 5135.9 Da, the expected values are:

    IonExpected m/z
    [M+4H]4+≈ 1285.0
    [M+5H]5+≈ 1028.2
    [M+6H]6+≈ 857.0
    [M+7H]7+≈ 734.7
    [M+8H]8+≈ 643.0

    Our current certificate matches that ladder to within 0.1 across the board, with labelled peaks at 734.8, 857.0 and 1028.2 and further peaks at 643.0 and 1285.0.

    A mass roughly 99 Da light is the signature to watch for, because it points to a missing valine and ties back to the Val13 problem in the databases. A 43-residue chain averages 5036.7. That deficit divides by the charge state, so the 5+ ion reads 1008.4 against an expected 1028.2, a shift of about 20 units at that charge.

    Lot Match and the Testing Lab

    Match the lot or batch identifier on the certificate to the one printed on the vial, then check that the laboratory named is an analytical lab. A blank lot field is common and worth querying with the supplier. Our 10 mg certificate carries a web verification code, and our quality testing process runs identity and purity on every batch, with heavy metals, endotoxin, and sterility on a rotating cycle. The case for third-party vs in-house peptide testing rests on exactly this independence.

    Net Peptide Content and Acetate

    Content and purity answer different questions. Purity is the share of the sample that is tesamorelin; content is how many milligrams of peptide are actually present. Our current certificate reports 10.64 mg by HPLC quantitation for the 10 mg vial. Acetate counter-ions are the reason the two figures rarely line up with the label weight.

    Storage of Lyophilized Tesamorelin

    Store sealed, lyophilized tesamorelin at −20 °C, protected from light, and keep it dry. The certificate for our 10 mg vial describes the material as a white lyophilized powder, which is the form that tolerates frozen storage best.

    Two handling habits help. Let a vial reach room temperature before opening it, so moisture does not condense onto cold powder, and plan how much material each piece of work needs in advance, because repeated freeze-thaw cycling is harder on a 44-residue peptide than on a short one.

    For assay preparation, tesamorelin is soluble in water and in DMSO.

    Research-Grade Tesamorelin in the US

    Life Link Research supplies tesamorelin in two vial sizes for laboratory work, both stocked and shipped from California. The tesamorelin 10mg research peptide is the standard working stock for programmes that run through more material, and the 2mg vial suits smaller-scale assay work.

    Every lot ships with a batch-matched certificate of analysis. To read the current one, open the product page and click View report, which opens the certificate library entry for that product with the active document and the earlier ones alongside it.

    Tesamorelin sits in the wider catalogue of GHRH and secretagogue research peptides, where the same testing workflow applies across the range. Identity runs by LC-MS and purity by RP-HPLC on every batch, with heavy metals, endotoxin, and sterility tested on a rotating cycle across the catalogue. Material is sold to qualified researchers aged 21 and over, for laboratory use.

    Tesamorelin FAQs

    How many amino acids are in tesamorelin?

    Tesamorelin has 44 amino acids. The chain matches human GHRH(1-44) exactly, running Tyr1 through Leu44, and it is annotated in UniProt entry P01286 as residues 32 to 75 of the somatoliberin precursor. Sequence strings showing 43 residues have usually dropped valine at position 13, which also costs them 99 Da of mass.

    What is the molecular weight of tesamorelin?

    The average molecular weight of tesamorelin is 5135.9 Da as the free base, from the formula C221H366N72O67S. The monoisotopic mass is 5132.72 Da. Published averages range from 5135.78 to 5136 across databases, and those differences are rounding artifacts.

    What is TH9507?

    TH9507 is the development code for tesamorelin and refers to the same compound. The code still appears in older literature, on supplier labels, and in database synonym lists. A certificate naming TH9507, or quoting the alternative registry number 804475-66-9, describes the same 44-residue peptide under CAS 218949-48-5.

    What is tesamorelin acetate?

    Tesamorelin acetate is the salt form the peptide is supplied in, written C221H366N72O67S·xC2H4O2 with x approximately 7. The acetate counter-ions pair with the peptide’s eight basic residues. They add roughly 420 Da to the 5135.9 Da free base, so gross vial weight runs about 8 percent above net peptide weight.

    Is tesamorelin the same as sermorelin?

    No. Both are GHRH analogs, and they differ in size and end-group chemistry. Sermorelin is the 29-residue fragment GHRH(1-29)-NH2 with a free amino terminus, at 3357.9 Da. Tesamorelin runs the full 44 residues with a trans-3-hexenoyl cap on Tyr1, at 5135.9 Da.

    Conclusion

    Tesamorelin is a well-characterised molecule with one quirk: the public records describing it do not all agree, and the disagreements are easy to miss. Count the residues, confirm valine at 13, use 5132.72 for the monoisotopic mass, and read the purity figure attached to your own lot.

    For Research Use Only. Not for use in diagnostic or therapeutic procedures. Full terms are set out in the research disclaimer.

  • What Is GLP-3 RT? Structure, Sequence and Research-Grade COA

    What Is GLP-3 RT? Structure, Sequence and Research-Grade COA

    Quick Answer

    GLP-3 RT is a synthetic 39-residue peptide carrying the research code LY3437943, with a 20-carbon fatty diacid chain attached to Lys17. That one sentence is harder to verify than it looks. Search “GLP-3 RT” in PubChem, and nothing comes back. The record holding its molecular formula is filed under the name “Triple G.” KEGG prints the sequence without marking the methyl group at position 13. Seven of the ten records a PubChem text search does return are impurity standards.

    This guide sorts that out. It covers what GLP-3 RT is made of, the full sequence, the identifiers that actually resolve, the receptor assays behind the triple-agonist label, and what a batch certificate should show.

    For Research Use Only. Not for use in diagnostic or therapeutic procedures.

    What is GLP-3 RT?

    Quick answer: GLP-3 RT is a synthetic peptide with the research code LY3437943, developed by Eli Lilly. In cell-based assays, it binds three class B G protein-coupled receptors: the GIP receptor (GIPR), the GLP-1 receptor (GLP-1R), and the glucagon receptor (GCGR). It is an investigational compound.

    The “triple agonist” label describes exactly that and nothing more. An agonist is a molecule that binds a receptor and switches it on, and GLP-3 RT does this at all three targets in transfected cell lines. Older peptides in the same structural family engage one receptor or two. GLP-3 RT engages three, which is why the shorthand “GLP-3” shows up on supplier listings even though no receptor by that name exists.

    LY3437943 is the development code Eli Lilly assigned the molecule, and it remains the most reliable search term across chemical databases. ChEMBL lists it under CHEMBL5095485 with the synonyms LY-3437943 and LY3437943 alongside the INN. The FDA’s own substance registry carries it under the unique ingredient identifier NOP2Y096GV, classified as a protein.

    GLP-3 RT belongs to the lipidated peptide class. The backbone is built by chemical synthesis, then a fatty acid chain is attached at a single position to give the molecule an albumin-binding motif. That design choice drives most of what follows.

    What is GLP-3 RT made of?

    Quick answer: GLP-3 RT is built from a 39-amino-acid backbone with four deliberate modifications: aminoisobutyric acid (Aib) at positions 2 and 20, an alpha-methylated leucine at position 13, a C-terminal amide, and a lipid side chain on Lys17 built from a C20 diacid joined through a gamma-glutamate and an AEEA linker.

    Each change does a specific structural job.

    ModificationPositionStructural purpose
    Aminoisobutyric acid (Aib)2A non-coded residue with two methyl groups on the alpha carbon. It blocks the dipeptidyl peptidase cleavage site that trims this peptide family at the N-terminus.
    Alpha-methyl-L-leucine13A second alpha-methylated residue. The extra methyl restricts backbone rotation and shields the position from proteolysis.
    Aminoisobutyric acid (Aib)20Stabilises the central helix. Aib strongly favours helical geometry, which is the conformation this peptide family adopts at its receptors.
    C20 diacid on Lys17, via gamma-Glu and AEEA17A 20-carbon fatty diacid attached through a gamma-glutamate spacer and an AEEA (8-amino-3,6-dioxaoctanoic acid) linker. The diacid is an albumin-binding motif.
    C-terminal amide39The terminal serine is amidated, which caps the C-terminus and removes one negative charge.

    Three of those residues are not among the twenty encoded amino acids, so GLP-3 RT cannot be made biologically. It is assembled by solid-phase peptide synthesis, with the lipid chain added at the protected Lys17 side chain during the build.

    The same C20 diacid and AEEA linker chemistry appears across this peptide class, which is why GLP-3 RT pairs cleanly with other lipidated peptides in a single vial. The Cagri-Reta blend chemistry runs on the same principle, with cagrilintide carrying its own C20 diacid through a gamma-glutamate.

    What is the GLP-3 RT sequence?

    Quick answer: The GLP-3 RT sequence is YXQGTFTSDYSILLDKKAQXAFIEYLLEGGPSSGAPPPS-NH2, where X marks aminoisobutyric acid at positions 2 and 20. Leu13 is alpha-methylated, Lys17 carries the lipid chain, and the C-terminal serine is amidated. The chain is 39 residues long.

    Read in blocks of ten:

    PositionsResiduesModifications in this block
    1 to 10Tyr Aib Gln Gly Thr Phe Thr Ser Asp TyrAib at 2
    11 to 20Ser Ile Leu Leu Asp Lys Lys Ala Gln Aibalpha-methyl-Leu at 13, lipid chain on Lys17, Aib at 20
    21 to 30Ala Phe Ile Glu Tyr Leu Leu Glu Gly Glynone
    31 to 39Pro Ser Ser Gly Ala Pro Pro Pro SerC-terminal amide on Ser39

    Note the two adjacent lysines at 16 and 17. Only the second carries the lipid. That pair is the single most common source of confusion when people transcribe the structure, because a drawing that attaches the chain to Lys16 looks almost identical at a glance.

    The final nine residues, PSSGAPPPS, form a proline-rich tail. Four of the chain’s prolines sit in that stretch, at positions 31, 36, 37, and 38. Prolines break helical structure, and the tail is flexible enough that it does not resolve in the published cryo-EM maps.

    The composition is worth reading closely, because it predicts exactly where this peptide degrades. Serine is the most common residue at five positions, followed by glycine, leucine and proline at four each. Only two aspartates appear, at positions 9 and 15, and only two glutamines, at 3 and 19.

    Line those positions up against the impurity standards catalogued in PubChem and every one maps onto a real residue. The beta-Asp9 and beta-Asp15 impurities are backbone rearrangements at the two aspartates. The Glu3 and Glu19 impurities are the two glutamines deamidating. D-Ser32 is one of the five serines epimerising. None of those positions is arbitrary, and knowing which residues are vulnerable tells you what a chromatogram’s shoulder peaks are likely to be.

    Common sequence errors

    Three errors circulate widely. AI-generated answers have returned a 41-letter string for this peptide, which is two residues too long. KEGG entry D12430 writes position 13 as a plain Leu, with no marking for the alpha-methyl group, and leaves out the C-terminal amide and the Lys17 lipid entirely. Wikipedia’s structural footnote labels are numbered independently of residue position, so reading them as positions puts every modification in the wrong place.

    Retatrutide's 39 residues with Aib at 2 and 20, alpha-methyl-Leu at 13 and the C20 diacid on Lys17, beside the electrospray charge-state ladder and the single MALDI ion.

    GLP-3 RT’s 39 residues with Aib at 2 and 20, alpha-methyl-Leu at 13 and the C20 diacid on Lys17, beside the electrospray charge-state ladder and the single MALDI ion.

    GLP-3 RT formula, molecular weight, and identifiers

    GLP-3 RT has the molecular formula C221H342N46O68, an average molecular weight of 4731.4 g/mol, and CAS number 2381089-83-2. The FDA registry identifier is NOP2Y096GV. Its KEGG drug entry is D12430, and its ChEMBL identifier is CHEMBL5095485.

    IdentifierValue
    Molecular formulaC221H342N46O68
    Average molecular weight4731.4 g/mol
    Monoisotopic mass4728.47 Da
    CAS number2381089-83-2
    UNIINOP2Y096GV
    KEGGD12430
    ChEMBLCHEMBL5095485
    Development codeLY3437943
    Length39 residues

    PubChem is the awkward one. A name search for “GLP-3 RT” returns no compound at all, and neither does the CAS number. The record that carries the correct formula is CID 171390338, whose only four synonyms are “Triple G,” orb1981169, EX-A7826E, and GTPL13769. The INN is absent from that record, which is precisely why the search fails.

    Run a text search instead, and PubChem returns ten records. Seven are named impurity standards: beta-Asp15, Glu3, des+Asp9, D-Ser32, Glu19, and beta-Asp9 variants, plus an unspecified Impurity 2. Four of those seven carry GLP-3 RT’s own formula and mass. Of the remaining three, one is a genuine sodium salt, one is labelled “GLP-3 RT (sodium salt)” while carrying the free-acid formula, and one sits under the supplier code WZG0211.

    That matters analytically. Four catalogued impurities are isomers of the real thing, identical in mass and distinguishable only by chromatography. A certificate that confirms mass alone has not ruled them out, which is the practical difference between HPLC vs mass spectrometry as identity methods.

    Average vs monoisotopic mass

    Two mass values appear for GLP-3 RT, and they measure different things. The average molecular weight, 4731.4 g/mol, uses the natural isotope mix of every element and is the figure to pair with a weighed sample. The monoisotopic mass, 4728.47 Da, uses only the lightest isotope of each element and is the figure a high-resolution mass spectrometer reports.

    PubChem shows a third number, an “ExactMass” of 4730.48, which sits 2.007 Da above the true monoisotopic value. PubChem’s separate MonoisotopicMass field agrees with KEGG at 4728.47. An MS report should be read against 4728.47 for high-resolution work, or against 4731.4 for average-mass instruments.

    Which receptors does GLP-3 RT bind?

    Quick answer: GLP-3 RT binds three class B G protein-coupled receptors: GIPR, GLP-1R and GCGR. Activity is measured as cyclic AMP accumulation in cell lines transfected with each receptor, the standard functional readout for this receptor class. Coskun and colleagues reported the original characterisation in Cell Metabolism in 2022.

    All three are secretin-family receptors that couple to the stimulatory G protein Gs. Binding the receptor activates adenylate cyclase, raising intracellular cAMP, and the assay reads that rise in a dish. Coskun and colleagues, 2022 ran the cAMP panel across the three receptors and reported the potency profile that established the triple-agonist description.

    The assay format explains why the word “agonist” is doing precise work here. Each receptor is expressed in a cell line engineered to carry it, so the signal comes from one receptor at a time. Potency is read off a concentration-response curve and reported as an EC50, the concentration producing half the maximum cAMP response. Running the same peptide across three separately transfected lines is what allows a single molecule to be characterised at three targets.

    Structural work followed. Li and colleagues published cryo-EM structures of GLP-3 RT bound to each receptor in Cell Discovery in 2024. The glucagon receptor complex is deposited as PDB 8YW5 at 2.84 Angstrom resolution, released 7 August 2024. Worth noting for anyone modelling the molecule: RCSB lists the GLP-3 RT chain in that entry as 30 residues, with modified residues AIB and 2ML present. The proline-rich C-terminal tail is disordered and not modelled.

    GLP-3 RT shares this receptor family with tesamorelin only at the class level. Tesamorelin acts at the GHRH receptor, a different class B target entirely.

    Is GLP-3 RT FDA approved?

    Quick answer: No. As of 9 November 2026, GLP-3 RT is investigational and has not been approved by the FDA. Eli Lilly’s statement of 23 July 2026 describes it as “an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist” and states that “Lilly plans to submit a Biologics License Application (BLA) for GLP-3 RT to FDA in Q1 2027.”

    ChEMBL records the same position independently, listing GLP-3 RT at max phase 3 with the first-approval field empty. The FDA substance registry holds the molecule under UNII NOP2Y096GV as a registered substance, which records its identity and carries no approval status of its own. Material supplied under this listing is for laboratory research only.

    What should a GLP-3 RT COA show?

    Quick answer: A GLP-3 RT certificate of analysis should show an HPLC chromatogram with the batch purity result, a mass-spectrometry identity confirmation, net peptide content in milligrams, the batch or sample identifier, the testing laboratory, and the date of analysis. Purity by HPLC varies from batch to batch, so the number that counts is the batch result printed on the certificate.

    On the mass-spectrometry page, the ion pattern depends on the instrument. Electrospray ionisation spreads the molecule across several charge states, so an ESI report shows a ladder of peaks.

    IonExpected m/z
    [M+3H]3+1578.1
    [M+4H]4+1183.9
    [M+5H]5+947.3
    [M+6H]6+789.6

    MALDI instruments produce one protonated ion near 4732.4. Both are valid identity confirmations, so a certificate showing a single peak at 4732 has not failed the ESI table above. It was run on a different instrument.

    Identity can also be confirmed chromatographically, by matching the sample’s retention time against a reference standard. That method is weaker on its own, because the four isomeric impurities catalogued in PubChem share GLP-3 RT’s mass, while a retention-time match carries no mass information at all. A certificate that reports both is stronger than one reporting either.

    Net peptide content is the figure that separates the weight of a vial from the weight of the peptide inside it. Piatkowski and colleagues tested three products sold as GLP-3 RT in Australia, each labelled 10 mg, and reported in Drug and Alcohol Review in 2026 that none matched their label: the three vials measured 5.13 mg, 16.5 mg and 19.0 mg of peptide. The authors note that “the quantity present varied substantially from the labelled content,” on a sample of three.

    Life Link’s current GLP-3 RT certificates report content directly. The 15 mg vial was analysed by Bioviridian on 19 June 2026, identity confirmed by MALDI-MS, content 15.96 mg, with a retention time of 11.078 minutes. The 10 mg vial was analysed by Prodigy Labs in San Diego, identity was confirmed by HPLC retention-time match, net peptide content 10.49 mg, alongside a fentanyl screen and five heavy metals by USP <232> and <233>, all not detected.

    Open either product page and click View report to read them. Reading a certificate closely is covered in how to verify a peptide COA, and what 98% vs 99% purity means explains why the second decimal place matters less than the method behind it. Our third-party testing runs identity and purity on every batch, with secondary panels on rotation.

    How is lyophilized GLP-3 RT stored?

    Quick answer: Lyophilized GLP-3 RT is stored sealed, dry, and desiccated, protected from light, at -20 degrees C for long-term storage. Let the vial reach room temperature before opening to limit condensation on the powder.

    The lipid chain makes GLP-3 RT more hydrophobic than an unmodified peptide of similar length, and the powder is hygroscopic, so an intact seal matters as much as the temperature. Handling details for powders of this type are in the peptide storage guide, and the stability trade-offs between formats are set out in lyophilized vs pre-mixed peptides.

    Solubility: Soluble in water or DMSO for assay preparation.

    GLP-3 RT for research: US supply

    Life Link Research supplies GLP-3 RT as a lyophilized powder in three vial sizes, each shipped with a batch certificate of analysis and dispatched same day from California on orders placed before 2 PM PST.

    The GLP-3 RT 15mg research vial is the standard working size, and its certificate file currently holds ten laboratory documents covering identity, purity, endotoxin, heavy metals, and microbial counts. Every document stays on the product page, so earlier analyses can be read alongside the current one. Smaller and larger programmes are served by the 10mg vial and the 20mg vial, supplied as the same lyophilized powder in different fill weights.

    Two formats pair GLP-3 RT with a second peptide in one order. Cagri-Reta 10/10mg combines it with cagrilintide, and the MAXMORPH kit (GLP-3 RT + tesamorelin) supplies both peptides as separate vials. The full catalogue of all GLP-family research peptides sits alongside them.

    GLP-3 RT FAQs

    Is GLP-3 RT a peptide?

    Yes. GLP-3 RT is a synthetic peptide of 39 amino acid residues, modified with a C20 fatty diacid side chain on Lys17. Three of its residues are non-coded, so it is assembled by solid-phase peptide synthesis. Its FDA substance registry entry classifies it as a protein.

    How many amino acids does GLP-3 RT have?

    GLP-3 RT has 39 amino acid residues. Two positions, 2 and 20, carry aminoisobutyric acid, a non-coded residue, and position 13 carries alpha-methyl-L-leucine. The C-terminal residue, Ser39, is amidated. Lys17 bears the C20 fatty diacid side chain.

    What is LY3437943?

    LY3437943 is the development code Eli Lilly assigned to GLP-3 RT , and it appears as LY-3437943 in some databases. It identifies the same molecule as the INN GLP-3 RT, with formula C221H342N46O68 and CAS number 2381089-83-2. It remains the most reliable search term across chemical registries.

    What is GLP-3 RT’s CAS number?

    GLP-3 RT’s CAS number is 2381089-83-2. A PubChem search on that number returns no compound record, so the CAS is best cross-checked against KEGG entry D12430 or the FDA unique ingredient identifier NOP2Y096GV, both of which resolve to the same 39-residue structure.

    Why does PubChem show several GLP-3 RT records?

    A PubChem text search returns ten records. Seven are named impurity reference standards, including beta-Asp and D-amino-acid isomers, and four of those carry GLP-3 RT’s own formula. Two more are sodium-salt entries, and one sits under a supplier code. The record holding the correct structure is filed under “Triple G.”

    Is GLP-3 RT a GLP-1 agonist?

    In receptor assays, GLP-3 RT activates the GLP-1 receptor along with the GIP and glucagon receptors, measured as cyclic AMP accumulation in transfected cell lines. Describing it as a GLP-1 agonist alone is incomplete, since all three receptors respond in the same assay panel.

    Disclaimer

    For Research Use Only. Not for use in diagnostic or therapeutic procedures. Full terms are set out in our research disclaimer.

  • CJC-1295 (No DAC) + Ipamorelin Blend 5/5mg: Composition, Ratio & COA

    CJC-1295 (No DAC) + Ipamorelin Blend 5/5mg: Composition, Ratio & COA

    Quick Answer

    This article covers what the cjc 1295 ipamorelin blend contains, both sequences and masses, the real molar ratio behind the 5/5 label, how a two-peptide certificate of analysis should be laid out, storage of the sealed vial, and current US regulatory status. Life Link Research supplies this material for laboratory research use only.

    Key takeaways

    • One vial, two peptides: 5 mg of Mod GRF(1-29), the no-DAC form of CJC-1295, plus 5 mg of ipamorelin
    • Identity: Mod GRF(1-29) is C152H252N44O42 at about 3,367.9 g/mol, CAS 863288-34-0; ipamorelin is about 711.9 g/mol
    • Equal milligrams are not equal molecules: 1.48 micromol against 7.02 micromol, a molar ratio of roughly 1 to 4.7 in favour of ipamorelin
    • No DAC in this vial; the DAC-bearing variant is C165H269N47O46 at about 3,647.2 g/mol, so the two separate by mass alone
    • COA check: two resolved HPLC peaks with separate purity figures, two confirmed masses, a measured amount for each peptide, plus lot, test date and named lab
    • Status: neither peptide is FDA approved as of November 7, 2026; supplied for laboratory research only

    A CJC-1295 (no DAC) + Ipamorelin 5/5mg blend is a single lyophilized vial containing 5 mg of Mod GRF(1-29) and 5 mg of ipamorelin. Equal milligrams, though, is where the symmetry stops. One of these molecules is roughly 4.7 times heavier than the other, so a vial labelled 5/5 contains almost five times as many ipamorelin molecules as Mod GRF molecules. That arithmetic shapes how the material is weighed out, how a certificate should report it, and what a single combined purity figure can and cannot tell you.

    Contents

    What is the CJC-1295 + Ipamorelin blend?

    It is a premixed lyophilized vial containing two synthetic peptides. Mod GRF(1-29), which suppliers also list as CJC-1295 without DAC, is a 29-residue GHRH-receptor ligand. Ipamorelin is a 5-residue ligand at GHSR-1a. The standard format is 5 mg of each, 10 mg total, equal by weight, and each peptide keeps its own structure in the vial.

    Nothing is bonded between them. Both peptides are dissolved, combined and freeze-dried together, which leaves two chemically separate compounds sharing one cake, one lot number and one certificate.

    Three label formats turn up across the category:

    • 5/5mg: The default, and the format covered here. 10 mg of peptide in total.
    • 10/10mg: The same equal weighting at double the fill, 20 mg in total.
    • “10mg” with no breakdown stated: Ambiguous. It may mean 5 mg of each or 10 mg of each, and only the certificate settles the question.

    That last one is the reason a label alone is a poor specification for a two-peptide vial. Choosing between peptide blends vs single vials turns on whether a fixed ratio or an adjustable one suits the work in hand.

    Is Mod GRF(1-29) the same as CJC-1295 no DAC?

    Yes. They are two names for one molecule, and the naming history explains the duplication. The compound was first described in the literature as a tetrasubstituted analogue of the first 29 residues of GHRH, shortened in practice to Mod GRF(1-29). The code CJC-1295 was attached to a longer-acting version carrying DAC, a lysine-maleimide group that binds the peptide to albumin after administration. Suppliers then applied the better-known CJC-1295 label to the unmodified 29-residue peptide and distinguished it by adding “no DAC”.

    Two names, one structure, and no maleimide group anywhere in this vial. CJC-1295 with DAC vs without DAC sets the two structures side by side, including the 279.3 g/mol the DAC group adds.

    What is in a 5/5mg vial?

    The vial contains two separate peptides. Mod GRF(1-29) has the formula C152H252N44O42 and an average mass of about 3,367.9 g/mol. Ipamorelin has the formula C38H49N9O5 and an average mass of about 711.9 g/mol. They are mixed before freeze-drying and are not chemically bonded, so each behaves as its own compound in every assay and on every chromatogram.

    PropertyMod GRF(1-29), CJC-1295 no DACIpamorelin
    Length29 residues, C-terminal amide5 residues, C-terminal amide
    SequenceTyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2Aib-His-D-2-Nal-D-Phe-Lys-NH2
    FormulaC152H252N44O42C38H49N9O5
    Average mass~3,367.9 g/mol (monoisotopic 3,366.90)~711.9 g/mol (monoisotopic 711.39); vendor sheets often print 711.85
    CAS863288-34-0170851-70-4
    PubChem CID568419459831659
    Receptor targetGHRH receptor, a class B GPCRGHSR-1a, a class A GPCR
    SolubilitySoluble in water for assay preparationSoluble in water for assay preparation

    Both CAS numbers were checked against PubChem on 7 November 2026 and resolve to the structures above. One caution applies to the Mod GRF record: PubChem CID 56841945 carries “CJC-1295 with DAC” among its synonyms even though the deposited structure has no DAC group, and a duplicate record, CID 91976842, repeats the same formula. The DAC form is a separate entry, CID 91971820, at C165H269N47O46 and about 3,647.2 g/mol. Anyone pulling identity data by name rather than by structure can land on the wrong one.

    Ipamorelin is the smaller and the stranger of the two, with three non-standard residues in five positions. Ipamorelin’s structure walks the Aib, D-2-Nal and D-Phe positions in sequence.

    The four substitutions in Mod GRF(1-29)

    Four positions carry substitutions against native GHRH(1-29): position 2 becomes D-Ala, position 8 Gln, position 15 Ala and position 27 Leu. Reading PubChem CID 56841945 residue by residue confirms all four, which is worth doing directly, because open-web sources disagree.

    Position 27 is the useful one for identity checking. Native GHRH carries Met at 27; Mod GRF carries Leu. A supplier sequence listing Met27 is either quoting the native peptide by mistake or describing something other than Mod GRF, and since Met and Leu differ by about 18 Da across a 3,367.9 g/mol chain, a mass figure alone will not always catch it. The written sequence on the certificate will.

    What does “5/5mg” mean, and what is the real ratio?

    5/5mg means equal weight, not equal numbers of molecules. Ipamorelin is about 4.7 times lighter than Mod GRF(1-29), so a 5/5mg vial carries roughly 7.0 µmol of ipamorelin against roughly 1.5 µmol of Mod GRF. In molar terms the vial is about 1:4.7, not 1:1.

    Equal milligrams, unequal molecules: a 5/5mg vial contains about 1.48 micromol of Mod GRF(1-29) against about 7.02 micromol of ipamorelin, a molar ratio of roughly 1 to 4.7

    Equal milligrams, unequal molecules: a 5/5mg vial contains about 1.48 micromol of Mod GRF(1-29) against about 7.02 micromol of ipamorelin, a molar ratio of roughly 1 to 4.7

    The maths

    5 mg ÷ 3,367.9 g/mol = 1.48 µmol of Mod GRF(1-29)
    5 mg ÷ 711.9 g/mol = 7.02 µmol of ipamorelin
    7.02 ÷ 1.48 = a molar ratio of about 1:4.7

    Why this is the number to carry into a protocol rather than the label: receptor assays are set up at molar concentrations, so a working solution made from a 5/5 vial arrives at the plate with nearly five times as much ipamorelin as Mod GRF on a per-molecule basis. A 1:1 weight blend and a 1:1 molar blend are different preparations, and only one of them is in the vial.

    One more layer runs under all of this. The 5 mg on the label is gross powder weight, which includes counter-ions and residual water alongside the peptide itself. The measured peptide in each milligram is a separate figure, covered in the certificate section below.

    Blend vs two separate vials: what changes chemically?

    Nothing changes in either molecule. Both peptides have the same sequence, mass and solubility whether they are freeze-dried together or apart. What a blend fixes is the ratio, set once at manufacture, and what it consolidates is the paperwork: one lot number and one certificate covering both compounds.

    The trade-off runs the other way for anyone who needs to vary the proportions. Two separately weighed vials let a laboratory set any molar ratio it chooses, including a true 1:1 by moles, and give each compound its own lot history. A premixed vial forecloses that, which is a reasonable price for the consistency it buys across a long run of plates, and the wrong choice for a concentration-response series on one peptide at a time.

    How CJC-1295 and ipamorelin differ comes down to receptor class and chain length, which is why the two are usually run on separate assay panels rather than one.

    How are these two peptides studied in the lab?

    Both are studied mainly with receptor assays. Mod GRF(1-29) is tested at the GHRH receptor and ipamorelin at GHSR-1a, with the readouts chosen to suit each receptor’s signalling class. The methods below describe what is measured, not what was found.

    MethodTargetStudy type
    Receptor binding, labelled ligand displacementGHRH receptor / GHSR-1aIn vitro
    cAMP accumulationGHRH receptorIn vitro
    Calcium flux or IP1 accumulationGHSR-1aIn vitro
    Receptor-null and knockdown controlsBothIn vitro
    Rodent modelsBothAnimal
    Circular dichroism, mass spectrometryBoth moleculesBiophysical

    The class difference explains why the readouts diverge. Gs coupling at the class B GHRH receptor makes cAMP accumulation the natural first readout, while Gq/11 coupling at the class A receptor GHSR-1a points to calcium flux or IP1 instead. A single assay panel rarely suits both, which is one practical consequence of a two-peptide vial that the label never mentions.

    What should a two-peptide blend COA show?

    A valid blend certificate reports each peptide separately. That means two resolved HPLC peaks with their retention times, two mass identities, a measured amount per compound, and a traceable header: which lot, tested when, by whom. One figure covering “the blend” is not a specification for either peptide in it.

    The expected mass readings follow from the two molecular weights. Mod GRF(1-29) at about 3,367.9 g/mol usually appears as a multiply charged ion, commonly [M+4H]⁴⁺ near m/z 843.0 or [M+3H]³⁺ near m/z 1,123.6. Ipamorelin at about 711.9 g/mol appears as [M+H]⁺ near m/z 712.9. A spectrum showing only one of these describes only one of the two peptides in the vial.

    What a two-peptide blend certificate of analysis should report for each compound, and the red flag attached to each field

    What a two-peptide blend certificate of analysis should report for each compound, and the red flag attached to each field

    COA fieldWhat to expectRed flag
    HPLC chromatogramTwo resolved peaks, each with a retention time and its own area percentageOne peak, or a single combined purity figure
    Mass identityBoth masses confirmed: ~843.0 or ~1,123.6 for Mod GRF, ~712.9 for ipamorelinOnly one mass reported, or no spectrum attached
    Sequence listingLeu at position 27 in the Mod GRF chainMet27, which is the native GHRH residue
    Measured amountMilligrams for each peptide, stated separatelyA single total, or label weight repeated as if measured
    Net peptide contentReported per peptide, not pooledOne figure covering both compounds
    Lot number and test dateBoth present, and matching the vialBlank, “not provided”, or a task number used as a lot
    Testing laboratoryNamed, and independent of the sellerUnnamed, or described only as “an independent lab”

    Life Link’s own documentation gives a worked example of why label weight and measured content differ. The current certificate for the single CJC-1295 no DAC 5mg vial, issued by Prime Analytical Labs in Concord, California, report RP218-29Apr26-1 dated 5 May 2026, reports 99.30% by HPLC and a net peptide content of 5.57 mg against a 5 mg label. Measured content above label weight is normal, because vials are filled with a margin so the label claim is met after counter-ions and residual moisture are accounted for. The figure a laboratory should record is the measured one.

    Third-party HPLC and mass-spec testing runs identity and purity on every batch, with heavy metals, endotoxin and sterility on a rotating cycle across the catalogue. Knowing how to verify a peptide COA means tracing the report back to the laboratory that issued it rather than taking the document at face value. Certificates are reached by opening the product and selecting View report.

    Purity is not content

    HPLC purity is the share of the target peptide among the UV-detected peaks, which says nothing about how much peptide a milligram of powder contains. Net peptide content is the second figure, typically 60% to 90% of gross weight, with trifluoroacetate or acetate counter-ions and residual water making up the rest.

    For a blend, those two figures cannot sensibly be pooled, and the reason is in the sequences. Mod GRF(1-29) carries three arginines, two lysines and a free N-terminal amine, so up to six basic sites can take a counter-ion. Using the standard estimate of about 114 g/mol per trifluoroacetate, a fully loaded chain would run near 83% peptide by weight. Ipamorelin, with one lysine, one histidine and its N-terminal amine across a far smaller molecule, carries a different load entirely. Two compounds with different counter-ion burdens in one vial need two content figures, and a certificate that reports one has averaged away the thing being measured.

    How should a lyophilized blend vial be stored?

    Keep sealed vials of the powder frozen at −20 °C, dry and away from light, and log the lot number against every experiment that draws on them. Avoid repeated freeze-thaw cycles of the sealed cake, and let a vial reach room temperature before opening so that moisture does not condense onto cold powder.

    Two residues set the shelf-life questions for this pair. Mod GRF(1-29) carries asparagine and several glutamines, which are the positions associated with deamidation in aqueous conditions, and ipamorelin’s two aromatic D-residues are the positions to watch for oxidation. Both are reasons the dry, dark, cold condition is the one to keep. Lyophilized peptide storage sets the temperature ranges by compound family, which differ from the sealed-vial condition described here.

    What is the regulatory status of CJC-1295 and ipamorelin in the US?

    Neither peptide is approved by the FDA, and both are supplied in the US as research chemicals. The FDA’s page on bulk drug substances that may present significant safety risks, current as of 22 April 2026, places them differently from one another, so a single statement covering both would be wrong.

    • CJC-1295: Listed under substances nominated for compounding but subsequently withdrawn. The agency states that it “has identified serious adverse events associated with CJC-1295” and notes that the available clinical data are limited.
    • Mod GRF(1-29): Absent from the page under that name. The FDA indexes this molecule as CJC-1295, so the entry above is the one that applies.
    • Ipamorelin acetate: Category 2 on the interim 503B list, added 29 September 2023, and also present in the withdrawn section. The stated concern relates to administration to people by the intravenous route.

    Positions above were read from the FDA’s own page on 7 November 2026. None of this bears on supply as a laboratory reagent, which is what this material is.

    CJC-1295 + Ipamorelin 5/5mg for research

    One vial, one lot, one batch certificate, shipped from stock in California. The CJC-1295 + Ipamorelin 5/5mg blend carries 5 mg of each peptide with identity by mass spectrometry and purity by reverse-phase HPLC on the batch, and the certificate is reached from the product page.

    Laboratories setting their own molar ratio, or running a concentration-response series on one compound at a time, want the two separately. CJC-1295 no DAC 5mg and ipamorelin 10mg are stocked as single vials with their own lot histories and certificates.

    CJC-1295 + Ipamorelin blend FAQs

    Is Mod GRF 1-29 the same as CJC-1295?

    Yes, when CJC-1295 is specified as the no-DAC form. Both names describe one molecule: a modified form of the first 29 residues of GHRH, CAS 863288-34-0, C152H252N44O42, about 3,367.9 g/mol. The DAC version is a different compound with a different formula, mass and CAS number.

    What does 5/5mg mean on a blend vial?

    It means the vial was filled with 5 mg of each peptide by weight, 10 mg in total, as a single freeze-dried cake. It describes gross powder weight at fill, not the measured peptide content, and not the number of molecules of each compound.

    What is the molar ratio in a 5/5mg CJC-1295 + Ipamorelin blend?

    About 1:4.7 in favour of ipamorelin. Dividing 5 mg by each molecular weight gives roughly 1.48 µmol of Mod GRF(1-29) and roughly 7.02 µmol of ipamorelin, because ipamorelin is about 4.7 times the lighter molecule. Equal milligrams produce unequal molar amounts.

    Does the blend contain DAC?

    No. DAC is the lysine-maleimide group carried by the longer-acting CJC-1295 variant, and it is absent here. The no-DAC peptide in this vial has the formula C152H252N44O42; the DAC-bearing compound is C165H269N47O46 at about 3,647.2 g/mol, so the two are separable by mass alone.

    How do I check a two-peptide blend COA?

    Look for everything twice. Two resolved HPLC peaks with retention times and separate purity figures, two confirmed masses, a measured amount for each peptide, plus a lot number, test date and named laboratory. A single pooled purity or content figure cannot describe either compound.

    Is the CJC-1295 / Ipamorelin blend FDA approved?

    No. Neither peptide is FDA approved, and the blend is not either. On the FDA’s bulk drug substances page, current as of 22 April 2026, CJC-1295 appears under nominations that were withdrawn, and ipamorelin acetate is Category 2 on the interim 503B list. Both are supplied in the US as research chemicals.

    For Research Use Only. Not for use in diagnostic or therapeutic procedures.

    Life Link Research supplies the CJC-1295 + Ipamorelin blend to qualified labs for in vitro study. Full terms are set out in the Life Link research disclaimer.

    References

  • What Is Thymosin Alpha-1? Structure, Research Use & COA

    What Is Thymosin Alpha-1? Structure, Research Use & COA

    Quick Answer

    Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide, acetylated at its N-terminus, with the formula C129H215N33O55. It carries an average molecular weight of 3108.3 g/mol, corresponds to residues 2 to 29 of the precursor protein prothymosin alpha, and is supplied in the United States for laboratory research use only. This page covers its sequence, its measured structure, how it differs from TB-500, and what a valid batch certificate should report.

    Key takeaways

    • 28 residues, acetylated at the N-terminus, Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN
    • C129H215N33O55, 3108.3 g/mol, CAS 62304-98-7, PubChem CID 16130571
    • Cut from prothymosin alpha (gene PTMA), residues 2 to 29
    • Nine acidic residues against four lysines, so the chain is strongly acidic
    • No cysteine, no methionine and no aromatic residues, which changes how it reads on HPLC and MS
    • Thymosin beta-4, the molecule behind the TB-500 name, is a different 43-residue peptide of about 4,963 Da

    Two peptides in the same catalogue carry the thymosin name, and roughly 1,855 daltons separate them. That one number settles which is which on a certificate, long before anything else on the page does. Thymosin Alpha-1 is the shorter of the pair: a 28-residue chain with an acetyl cap on one end, nine acidic residues along it, and a molecular weight of 3108.3.

    Most of what is published about Tα1 reads as pharmacology. The chemistry underneath it is simpler and far easier to check, and it is the part that decides whether the material in a vial is the right molecule. What follows keeps to that: the sequence, the structure measured by NMR, the arithmetic behind the mass, and the certificate fields that confirm all of it.

    What is Thymosin Alpha-1?

    Quick answer: Thymosin Alpha-1 is a 28-residue peptide with an acetylated N-terminus. It matches residues 2 to 29 of the precursor protein prothymosin alpha, the product of the PTMA gene. Its sequence was determined in 1977, and research material today is built by solid-phase synthesis. Thymalfasin is its INN name.

    The name shortens to Tα1, written Ta1 or alpha-1 thymosin where Greek characters are awkward, and all three refer to one molecule. Thymalfasin is the International Nonproprietary Name assigned to the same 28-residue chain, so a listing using either term describes identical chemistry.

    Its sequence was worked out in 1977 and published in the Proceedings of the National Academy of Sciences, volume 74, pages 725 to 729 (PMID 265536), from a purified subfraction of the protein preparation then called thymosin fraction 5. That paper is the origin point for every identity record the peptide carries today.

    Research material is no longer purified from tissue. It is assembled by solid-phase peptide synthesis, one residue at a time on a resin, then cleaved, purified by reverse-phase HPLC and freeze-dried. At 28 residues the chain runs long for a synthetic peptide and well short of a protein, which is close to where the line between what peptides are and proteins is usually drawn. Synthesis also explains two things a buyer sees later: the salt form left behind by the purification step, and the net peptide content figure on the certificate.

    Where the sequence comes from: prothymosin alpha

    Prothymosin alpha is catalogued in UniProt as P06454, where the chain runs to 111 residues. The initiator methionine is removed in the processed form, leaving 110 residues with an acetyl group on the serine that becomes position 2. Tα1 is the stretch from residue 2 to residue 29 of that precursor, which is why the shorter peptide already arrives acetylated: the cap is the precursor’s own.

    UniProt annotates the entire 111-residue chain as disordered, with acidic residues concentrated across positions 40 to 84. The 28-residue segment inherits that character, which shapes everything from its behaviour on a column to its shape in water.

    What is Thymosin Alpha-1’s structure?

    Quick answer: Tα1 is a linear 28-mer, Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN, with the formula C129H215N33O55 and an average molecular weight of 3108.3 g/mol. Nine of its residues are glutamate or aspartate against four lysines, making the chain strongly acidic, and in plain water it takes no fixed shape.

    PropertyValue
    SequenceAc-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH
    One-letter codeAc-SDAAVDTSSEITTKDLKEKKEVVEEAEN
    Length28 residues
    ModificationN-terminal acetylation
    FormulaC129H215N33O55
    Molecular weight3108.3 g/mol (PubChem CID 16130571; Wikipedia gives 3108.315, a rounding difference)
    Monoisotopic mass3106.50 Da
    CAS62304-98-7
    UniProtP06454, residues 2 to 29
    PDB2L9I
    SolubilitySoluble in water for assay preparation

    Count the acidic residues and the chain’s character becomes obvious. Six glutamates and three aspartates give nine negative charges, four lysines give four positive ones, and the acetyl cap removes the free amine that would normally add another. Net charge at neutral pH lands near minus six, which is why the peptide is described as highly acidic and why it elutes early on a reverse-phase column.

    What the sequence leaves out influences the analytics just as much. There is no cysteine, so no disulfide chemistry to preserve or scramble. There is no methionine, so the plus-16 oxidation peak that complicates many peptide traces cannot appear. And with no tryptophan, tyrosine or phenylalanine anywhere in the chain, Tα1 absorbs almost nothing at 280 nm, so HPLC detection has to run on the peptide bond itself at 214 or 220 nm. A certificate reporting purity at 280 nm for this molecule would be describing the wrong measurement.

    One number ties the rest together. A 10 mg quantity of Tα1 is 3.22 micromoles, against 2.01 micromoles for the same gross weight of thymosin beta-4.

    Its shape in solution (NMR)

    In water alone, Tα1 shows no stable fold. The conformation that has been measured comes from a biophysical study by Elizondo-Riojas and colleagues, published in Biochemical and Biophysical Research Communications in 2011, volume 416, pages 356 to 361 (PMID 22115779) and deposited as PDB entry 2L9I. Working at 800 MHz in 40% trifluoroethanol and 60% water, the authors resolved an alpha-helix spanning residues 14 to 26, plus two double beta-turns within the first twelve residues that together form a distorted helical arrangement.

    Trifluoroethanol is a helix-promoting cosolvent, so those features describe what the chain can adopt under those conditions. They record a conformational preference under helix-promoting conditions, and behaviour in an aqueous buffer is a separate measurement.

    Thymosin Alpha-1 vs TB-500 (thymosin beta-4): are they the same?

    Quick answer: No. They are two different peptides that share the thymosin family name. Tα1 runs 28 residues at about 3,108 Da. Thymosin beta-4 runs 43 residues at about 4,963 Da. They come from different precursor genes, PTMA and TMSB4X, and both start with an acetylated Ser-Asp pair. TB-500 is a vendor name used for Tβ4 or a short fragment of it.

    Thymosin Alpha-1Thymosin beta-4
    Residues2843
    FormulaC129H215N33O55C212H350N56O78S
    Molecular weight3108.3 g/molabout 4,963 g/mol
    Precursor genePTMA (UniProt P06454)TMSB4X (UniProt P62328)
    N-terminal startAc-SD...Ac-SD...
    CAS62304-98-777591-33-4
    PubChem CID1613057116132341
    Sulfur atomsnoneone (Met6)
    On a COAMS ions consistent with 3108.3MS ions consistent with about 4,963

    The shared Ac-SD opening is the detail that trips people up, because the first two residues of the two chains are identical and both carry the same acetyl cap. Everything after that diverges, and the formulas make it plain: the single sulfur atom in the beta-4 formula belongs to its methionine at position 6, the residue that can pick up 16 daltons through oxidation. Tα1 contains no sulfur at all, so that peak has no chemical route to appear on its trace.

    The label is the other complication. Material sold as thymosin beta-4 (TB-500) is sometimes the full 43-residue peptide and sometimes the seven-residue fragment Ac-LKKTETQ at around 889 Da, and the identity result on the certificate is what separates those two. None of that ambiguity touches Tα1, which maps to one sequence and one registry entry.

    How is Thymosin Alpha-1 studied in the lab?

    Quick answer: Published Tα1 work runs through three method classes: biophysical structure determination, receptor-binding and expression assays in cultured cell lines, and rodent models. The receptors named in the in vitro work are TLR2 and TLR9.

    MethodModelStudy type
    NMR conformation analysisTrifluoroethanol and membrane-mimetic solventsBiophysical
    Toll-like receptor binding (TLR2, TLR9)Cultured cell linesIn vitro
    Gene and protein expression readoutsCell culturesIn vitro
    Rodent studiesAnimal modelsAnimal

    Two review articles indexed in PubMed Central, PMC7747025 and PMC7115394, cover the method record across those categories. Both are secondary literature, so the assay conditions they summarise trace back to the original papers rather than to the reviews themselves.

    Two points are useful for anyone reading that literature. Biophysical work on Tα1 is routinely run in cosolvent systems instead of plain buffer, because the peptide adopts no measurable fold without one, so solvent composition belongs in any comparison between structural papers. And the in vitro receptor work is identified by receptor name, TLR2 and TLR9, which makes method-level comparison between papers straightforward even where the systems differ.

    Laboratory research of this kind is the only setting the material is supplied for. Nothing in the published record constitutes an approved application.

    What should a Thymosin Alpha-1 COA show?

    Quick answer: A valid Tα1 certificate reports identity by ESI-MS consistent with 3108.3, HPLC purity as a batch result with its chromatogram, net peptide content, the lot number, the test date, the testing lab, the salt form, and endotoxin where that panel was run. The lot on the certificate has to match the lot printed on the vial label.

    COA fieldValue to expectRed flag
    Identity (ESI-MS)A multiply-charged ion series consistent with 3108.3A reported neutral mass near 3,066, which is the chain missing its acetyl cap
    Purity (RP-HPLC)A batch figure with the chromatogram attached, detection at 214 or 220 nmA flat “99%” with no trace, or purity read at 280 nm
    Net peptide contentA stated percentage or milligram figure for the vialAbsent, leaving gross weight as the only number
    Lot or batch numberA number matching the vial labelBlank, or the lab’s task number reused as the batch
    Test dateDated within the batch’s lifeUndated, or years older than the vial
    Testing labA named independent laboratoryAn unattributed in-house report
    Salt formAcetate or trifluoroacetate, statedUnstated, which leaves net content unexplained
    EndotoxinA result in EU/mg where testedA claim with no report behind it

    The mass arithmetic is the quickest check on the list. An acetyl group adds 42 daltons, so a chain reported near 3,066 is the unacetylated 28-mer rather than Tα1. On an ESI trace the difference appears as roughly 14 m/z units on the triply-charged ion, with Tα1 producing a charge ladder near m/z 1037, 778 and 623 for the 3+, 4+ and 5+ states.

    Thymosin Alpha-1 ESI-MS charge ladder: 3+ at m/z 1037.1, 4+ at 778.1, 5+ at 622.7 for a neutral mass of 3108.3, with the unacetylated 3,066 red flag

    Thymosin Alpha-1 ESI-MS charge ladder: 3+ at m/z 1037.1, 4+ at 778.1, 5+ at 622.7 for a neutral mass of 3108.3, with the unacetylated 3,066 red flag

    Purity and identity answer different questions, which is why both belong on the page. HPLC tells you how much of the material is one species; mass spectrometry tells you which species it is. Life Link publishes third-party HPLC and mass-spec testing on every batch, with secondary panels such as heavy metals and endotoxin running on rotation, and the Thymosin Alpha-1 10mg certificate page currently carries four lab documents against that single product. Reading one properly is a short exercise once you know how to verify a peptide COA against the vial in front of you.

    Net peptide content, salt form and endotoxin

    A 10 mg vial rarely contains 10 mg of peptide. The rest is counterion and residual water, and net peptide content is the figure that quantifies the difference. Bachem, one of the larger peptide manufacturers, defines it in its quality-control guide as “the percentage of peptides relative to non-peptidic material” and makes the distinction from purity explicit: “NPC and purity are not equivalent, because the former includes peptidic contaminants.” Water is measured separately, usually by Karl Fischer titration.

    Counterion chemistry follows the sequence. Reverse-phase purification leaves trifluoroacetate behind, and in Tα1 the only residues it can pair with are the four lysines, so an acetate-exchanged batch and a TFA batch will not report the same net content for the same gross weight.

    How should lyophilized Thymosin Alpha-1 be stored?

    Quick answer: Keep sealed vials of the powder at minus 20 °C, dry and shielded from light, and record the lot number alongside whatever the vial is used for. Lyophilized Tα1 is stable in that state; moisture and repeated warming are the conditions that degrade it.

    Two of the usual peptide storage worries do not apply here. With no cysteine there is no disulfide bond to scramble, and with no methionine there is no oxidation-prone side chain to protect from air. The chemistry left to guard against in a chain this acidic is moisture-driven, principally deamidation at its single asparagine and isomerisation at its three aspartates, which is why a dry, sealed, cold vial does most of the work.

    The same conditions apply to every freeze-dried research peptide, and the general rules for lyophilized peptide storage apply to Tα1 without modification. Record the lot number when a vial is opened, since the certificate is only traceable through it.

    What is Thymosin Alpha-1’s regulatory status in the US?

    Quick answer: Thymosin Alpha-1 is not approved by the FDA in the United States, and no approved product record exists for thymalfasin in the FDA’s Drugs@FDA database. It is supplied here as a research chemical, for laboratory use only. This status was checked on November 7, 2026.

    The clearest primary record is the Pharmacy Compounding Advisory Committee meeting of December 4, 2024. FDA proposed that thymosin alpha-1 free base and thymosin alpha-1 acetate not be included on the 503A Bulks List, and the committee voted 4 in favour and 17 against placing each form on that list, according to the FDA’s Final Summary Minutes approved on February 21, 2025.

    Later federal activity has not changed that. Appendix B of the HHS interim 503A peptide enforcement policy names six substances: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. Thymosin alpha-1 is not among them. A committee vote and an enforcement policy are procedural steps, and neither is an approval.

    Thymosin Alpha-1 10mg for research

    Life Link supplies Thymosin Alpha-1 10mg research peptide as a lyophilized powder at $116 a vial, falling to $92.80 a vial on orders of ten or more. Each batch carries its own certificate, and the product’s certificate page currently lists four lab documents, including the current report plus a heavy metals and endotoxin panel.

    Orders placed before 2 PM PST ship the same day from California by UPS 2-Day Air, with free shipping over $250. Material is sold to qualified researchers for laboratory use only.

    Thymosin Alpha-1 FAQs

    Is Thymosin Alpha-1 the same as TB-500?

    No. Thymosin Alpha-1 is a 28-residue peptide of about 3,108 Da encoded within the PTMA gene product. TB-500 is a vendor name for thymosin beta-4, a 43-residue peptide of about 4,963 Da from the TMSB4X gene, or for a seven-residue fragment of it. They share a family name and nothing else.

    How many amino acids are in Thymosin Alpha-1?

    Twenty-eight. The chain reads Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN and corresponds to residues 2 to 29 of prothymosin alpha, which UniProt records as a 111-residue precursor. Nine of the 28 residues are glutamate or aspartate, and four are lysine.

    What is the molecular weight of Thymosin Alpha-1?

    The average molecular weight is 3108.3 g/mol for the free peptide, from PubChem CID 16130571, with a monoisotopic mass of 3106.50 Da. A salt form adds the counterion mass on top of that figure, which is one reason a certificate states the salt alongside the weight.

    Is Thymosin Alpha-1 the same as thymalfasin?

    Yes. Thymalfasin is the International Nonproprietary Name for the same 28-residue acetylated chain, and both names resolve to CAS 62304-98-7 and PubChem CID 16130571. A supplier listing either term is describing one molecule with one set of identity data.

    Why is Thymosin Alpha-1 acetylated?

    The acetyl group is inherited from its precursor, where the serine at position 2 carries that cap after the initiator methionine is removed. Chemically it blocks the free N-terminal amine and adds 42 daltons, so an unacetylated 28-mer reads near 3,066 on a mass spectrum instead of 3,108.

    Is Thymosin Alpha-1 FDA approved?

    No. There is no approved product record for thymalfasin in Drugs@FDA. In December 2024 an FDA advisory committee voted 4 to 17 against placing thymosin alpha-1 free base and acetate on the 503A Bulks List, and the 2026 interim 503A peptide enforcement policy does not name the substance.

    For Research Use Only. Not for use in diagnostic or therapeutic procedures.

    Life Link Research supplies Thymosin Alpha-1 to qualified labs for in vitro study. Full terms are set out in the Life Link research disclaimer.

    References

  • What Is Epithalon (Epitalon)? AEDG Structure, Research Use & COA

    What Is Epithalon (Epitalon)? AEDG Structure, Research Use & COA

    Quick Answer

    Epithalon (Epitalon, AEDG) is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly, modeled on the amino-acid composition of the natural extract epithalamin. Its formula is C14H22N4O9 and it weighs 390.35 g/mol, registered under CAS 307297-39-8. It is supplied as a lyophilized powder for laboratory research use only.

    Key takeaways

    • Sequence: H-Ala-Glu-Asp-Gly-OH, four residues, free N-terminus and free C-terminus
    • Identity: C14H22N4O9, 390.35 g/mol average (390.1387 Da monoisotopic), CAS 307297-39-8, PubChem CID 219042
    • Epithalon, Epitalon and Epithalone are three spellings of one molecule; epithalamin is a different material, a natural extract with no single mass
    • COA check: an HPLC chromatogram plus an MS ion near 391.4 ([M+H]+), with the lot number, test date and salt form matching the vial label
    • Status: no FDA approval for any use as of November 7, 2026; supplied for laboratory research only

    Epithalon (also spelled Epitalon) is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly (AEDG). Its formula is C14H22N4O9, and it carries no ring, no cap and no unusual residue: four standard amino acids in a straight line. So what is Epithalon to a lab that orders it? Mostly a question of paperwork. With a structure this plain, the identity check, the purity trace and the salt form decide whether a vial is what its label says.

    The name trips people up too. Epithalon often gets mixed up with epithalamin, the natural extract it was modeled on, and the two are different materials.

    This guide covers its origin, chemical structure, the assays used to study it, what a sound Epithalon COA shows, how to store the powder and where it stands with the FDA.

    What Is Epithalon?

    Quick answer: Epithalon is a synthetic tetrapeptide, Ala-Glu-Asp-Gly, whose design was based on the amino-acid composition of epithalamin, a natural polypeptide extract. Vladimir Khavinson’s group in St. Petersburg, Russia, patented its synthesis in 2000. Today the epithalon peptide is supplied as a lyophilized research material made by chemical synthesis.

    The design story starts with an analysis, not a discovery. Khavinson’s team looked at which amino acids dominated epithalamin and built a four-residue peptide from them. A 2025 review in the International Journal of Molecular Sciences marks June 2025 as 25 years since that synthesis was patented.

    Epithalon shows what peptides are at a very small scale: amino acids joined by amide (peptide) bonds, here just four residues and three bonds, which is all “tetrapeptide” means.

    The line between Epithalon and epithalamin is sharp:

    • Epithalamin: A natural polypeptide extract, a mixture of many peptides with no single sequence, formula or mass.
    • Epithalon: One defined molecule with one CAS number, one PubChem record and one expected mass.

    A team of physicians from Johns Hopkins and Harvard Medical School drew the same line in an October 2026 narrative review (Jain et al., Int J Mol Sci). They describe epitalon as “a synthetic tetrapeptide developed from the amino-acid composition of epithalamin” and assess the epithalamin papers separately.

    Epithalon vs Epitalon vs Epithalone: Is It the Same Peptide?

    Yes. It’s one molecule with three transliterations of the original Russian name.

    • Epitalon: The spelling used in most journal papers and in the FDA’s own listings.
    • Epithalon: The spelling common on supplier catalogs, closer to “epithalamin.”
    • Epithalone: A rarer variant seen on older pages.

    All three point to CAS 307297-39-8 and PubChem CID 219042. In any epitalon vs epithalon comparison, then, only the spelling differs. AEDG, its one-letter code, is the spelling-free way to say the same thing.

    What Is Epithalon’s Chemical Structure?

    Quick answer: Epithalon is a linear peptide of four residues, alanine, glutamic acid, aspartic acid and glycine, with a free N-terminus and a free C-terminus. Its formula is C14H22N4O9, it weighs 390.35 g/mol, and it’s registered under CAS 307297-39-8.

    PropertyValue
    SequenceH-Ala-Glu-Asp-Gly-OH
    One-letter codeAEDG
    Length4 residues
    FormulaC14H22N4O9
    Molecular weight390.35 g/mol (average)
    Monoisotopic mass390.1387 Da
    CAS number307297-39-8
    PubChem CID219042
    Net charge at neutral pHAbout −2
    SolubilitySoluble in water for assay preparation
    AEDG residue map with charges, expected mass-spec ions and the three look-alike materials

    AEDG residue map with charges, expected mass-spec ions and the three look-alike materials

    Residue-by-Residue Breakdown

    Each residue adds something specific:

    • Ala (A): A small methyl side chain. Its free amine at the N-terminus is the molecule’s only basic site, carrying a +1 charge at neutral pH.
    • Glu (E): A side chain ending in a carboxylic acid, negatively charged at neutral pH.
    • Asp (D): A shorter acidic side chain, also negative. Followed by glycine, it forms an Asp-Gly pair, the sequence most prone to rearranging into isoaspartate during synthesis and storage.
    • Gly (G): The only residue without a side chain. Its free C-terminal carboxyl adds the third negative charge.

    Three acidic groups against one basic group leave AEDG at roughly −2 overall. That charge, plus a calculated XLogP of −5.5 on PubChem, makes AEDG strongly water-loving and acidic.

    Epithalon vs Epithalamin vs N-Acetyl Epitalon Amidate

    These are three different materials, so their COAs read differently.

    MaterialWhat it isMolecular weight
    Epithalon (AEDG)Synthetic tetrapeptide, free ends390.35 g/mol
    N-acetyl Epitalon amidateAEDG with an acetyl cap and C-terminal amideAbout 431.4 g/mol (calculated)
    EpithalaminNatural polypeptide extractNo single value

    A buyer should check that the COA’s mass matches the material ordered. A report showing about 431 belongs to the capped version, not plain Epithalon.

    How Is Epithalon Studied in the Lab?

    Quick answer: Published Epithalon research mostly uses cell-line assays and animal models, and human data is limited. Common methods include telomerase activity (TRAP) assays, gene-expression qPCR, immunofluorescence imaging, computer docking against histone proteins and rodent studies.

    Assay typeModelStudy typeSource
    Telomerase activity (TRAP) assayHuman cell lines and normal fibroblastsIn vitroAl-dulaimi et al., 2025
    C-circle assay and PML-body imaging (ALT markers)Human cell linesIn vitroAl-dulaimi et al., 2025
    Gene expression (RT-qPCR)Human gingival mesenchymal stem cellsIn vitroKhavinson et al., 2020
    Immunofluorescence with confocal microscopySame stem-cell culturesIn vitroKhavinson et al., 2020 (PubMed 32019204)
    Peptide–histone dockingMolecular modelling of histones H1, H2b, H3 and H4In silicoKhavinson et al., 2020
    Rodent studiesMice and ratsAnimalAraj et al., 2025 (review)

    Two details shape how to read this table. First, most of the record comes from a small number of groups, led for decades by Khavinson’s institute. Second, the 2025 cell study by Al-dulaimi and colleagues used control lines with known telomerase and ALT status, which lets each assay be checked against a reference.

    The 2025 review closes on a note many lab teams share: “this additionally justifies the necessity of further studies on this unusual tetrapeptide.”

    What Should an Epithalon COA Show?

    Quick answer: A valid Epithalon COA shows identity by mass spectrometry (expected [M+H]⁺ about 391.4), purity by HPLC as a batch figure, a lot or sample number and test date, the lab’s name and the salt form. Every one of those details should match the vial label.

    Field on the COAExpected entryRed flag
    IdentityMS mass near 391.15 (monoisotopic [M+H]⁺) or 391.4 (average)A mass that doesn’t match 390.35 g/mol
    PurityHPLC area %, with the chromatogram and detection wavelengthA fixed “99%” with no chromatogram
    Net peptide contentMeasured mg of peptide in the vialMissing, or far below the label
    Salt formFree base, acetate or TFANot stated
    Lab and reportLab name, address, report number, signaturesNo traceable lab
    Batch linkLot or sample number, test date, matching labelNo way to tie the report to the vial

    Prime Analytical Laboratories, an independent lab in Concord, California, issued Life Link’s current Epithalon batch report in April 2026. It shows 99.27% purity by HPLC and 12.26 mg of net peptide content, so the vial carries slightly more peptide than its 10 mg label.

    HPLC and MS check different things here. The Asp-Gly rearrangement noted earlier produces isoaspartate, a by-product with exactly the same mass as AEDG, so a mass reading alone can’t flag it. A clean, single main peak on the HPLC trace is what separates the two. That’s why third-party HPLC and mass-spec testing pairs the two methods instead of relying on one.

    Independent testing data show why batch reports deserve a close look. Finnrick, a public peptide-testing platform, lists eight Epithalon tests logged between February and September 2026, and four of the six completed tests didn’t pass its scoring criteria. Those failures are the reason to know how to verify a peptide COA before a vial goes into an experiment: match the mass, the chromatogram and the sample number to the label.

    Why the Salt Form (TFA vs Acetate) Changes the Numbers

    A lyophilized peptide’s gross weight includes counterions and bound water, not just the peptide. Araj and colleagues note that most commercial Epitalon comes as an acetate or TFA salt. Since AEDG has only one basic site, it binds at most about one counterion per molecule, and a heavier counterion means less peptide per milligram of powder.

    That’s why net peptide content and gross weight can differ on the same COA. Weighing adds its own error, too: a 2026 American Peptide Society research summary of work from William Lubell’s lab at the Université de Montréal notes that residual TFA can “make that weighing step a genuine source of error.”

    Peptide share per 10 mg of powder for Epithalon free base, acetate and TFA salt forms

    Peptide share per 10 mg of powder for Epithalon free base, acetate and TFA salt forms

    How Should Lyophilized Epithalon Be Stored?

    Quick answer: Keep sealed vials of Epithalon powder frozen at −20 °C, kept dry and shielded from light. Dry powder is the peptide’s most stable form, and moisture is the main thing to keep out.

    A few habits protect the powder:

    • Seal: Leave the vial closed until the day it’s needed.
    • Temperature: Store at −20 °C for the long term and avoid repeated warm-cold cycles.
    • Moisture: Let a frozen vial warm to room temperature before the cap comes off, which stops condensation from wetting the cake.
    • Light: Store vials in their box or an opaque container.

    Dryness counts double for AEDG. Water drives the Asp-Gly rearrangement, so a dry, cold cake keeps the HPLC profile closest to the one on the COA. Cold, dark and dry are the constants of lyophilized peptide storage for any sequence, and for AEDG, keeping moisture out comes first.

    What Is Epithalon’s Regulatory Status in the US?

    Quick answer: Epithalon has no FDA approval for any use. US suppliers sell it only as a research chemical for laboratory study.

    The FDA’s compounding page on bulk substances, current as of April 22, 2026, lists epitalon under “nominated but withdrawn.” It doesn’t appear among Category 2 substances.

    Three months later, on July 24, 2026, the Pharmacy Compounding Advisory Committee reviewed Epitalon (free base) and Epitalon acetate as possible additions to the 503A bulks list. The FDA’s meeting page carries the briefing documents. Then, on October 28, 2026, HHS filed an interim enforcement-discretion policy for 503A compounding, published in the Federal Register on October 30, that names Epitalon acetate among six peptides. It’s a compounding policy while the FDA writes the bulks-list rule, not a drug approval. Epitalon was one of seven compounds in the FDA’s July 2026 peptide review, and the committee’s advice doesn’t change its status as a research chemical.

    Epithalon 10mg for Research

    Life Link’s Epithalon 10mg research peptide comes as a single vial of lyophilized powder with its batch COA on the product page (open the product and click “View report”). Stock ships from California: anything ordered by 2 PM PST goes out the same day via UPS 2-Day Air, and multi-vial orders get quantity pricing.

    At four residues, Epithalon is one of the shortest sequences in the catalog: DSIP runs to nine residues, and MOTS-c, a peptide coded by mitochondrial DNA, to 16. Like Epithalon, both are sold strictly for lab study.

    Epithalon FAQs

    Is Epithalon the Same as Epitalon?

    Yes. Epithalon and Epitalon are two spellings of one molecule, and Epithalone is a third. All three share CAS 307297-39-8, PubChem CID 219042 and the sequence Ala-Glu-Asp-Gly. “Epitalon” is more common in journals, while “Epithalon” turns up more often on supplier catalogs.

    What Does AEDG Stand For?

    AEDG is the one-letter code for Epithalon’s four amino acids, starting at the N-terminus: A for alanine, E for glutamic acid, D for aspartic acid and G for glycine. The three-letter form is Ala-Glu-Asp-Gly. Researchers often write “AEDG peptide” to avoid the spelling question altogether.

    What Is the Molecular Weight of Epithalon?

    Epithalon weighs 390.35 g/mol on average, based on its formula, C14H22N4O9. Its monoisotopic mass is 390.1387 Da, the value high-resolution mass spectrometry targets. Salt forms weigh more per molecule, so an acetate or TFA salt has a higher formula weight than the free base.

    Is Epithalon FDA Approved?

    No. The FDA hasn’t approved Epithalon for any use. An FDA advisory committee discussed it for the compounding list in July 2026, and an October 2026 HHS compounding policy names Epitalon acetate, but neither step is a drug approval. US suppliers offer it as a research chemical only.

    How Much Does Epithalon 10mg Cost for Research?

    Prices change with stock and order size, so the live product listing shows the current figure. Life Link’s Epithalon 10mg page lists the single-vial price plus lower per-vial pricing on 3, 5 and 10 vials, along with the batch COA for the vial being sold.

    Is Epithalon a Peptide or a Supplement?

    Epithalon is a synthetic research peptide, not a dietary supplement. It’s made by chemical synthesis, supplied as a lyophilized powder and sold for laboratory research only. It has no approved use, and research suppliers don’t label it for use in people or animals.

    For Research Use Only. Not for use in diagnostic or therapeutic procedures.

    Life Link Research supplies Epithalon to qualified labs for in vitro study. Full terms are set out in the Life Link research disclaimer.

    References

  • What Is Melanotan 2? MT-II Structure, Receptors & COA

    What Is Melanotan 2? MT-II Structure, Receptors & COA

    Quick Answer

    Melanotan 2 (MT-II) is a seven-residue cyclic analog of α-MSH, closed by an Asp-Lys lactam bridge. It is a potent, non-selective agonist at MC1R, MC3R, MC4R and MC5R in cell-line assays, which is why labs use it as a reference ligand. Formula C50H69N15O9, 1024.2 g/mol, CAS 121062-08-6.

    Key takeaways

    • Sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a 23-membered lactam ring
    • Identity: C50H69N15O9, 1024.2 g/mol, CAS 121062-08-6, PubChem CID 92432
    • Receptors: low-nanomolar at MC1R, MC3R, MC4R and MC5R; no meaningful activity at MC2R
    • COA check: an HPLC chromatogram plus an ESI-MS ion near 1025.2 ([M+H]+)
    • Status: no FDA approval for any use as of November 4, 2026; supplied for laboratory research only

    Melanotan 2 is a synthetic peptide of seven amino acids, closed into a ring, modeled on the receptor-binding stretch of alpha-melanocyte-stimulating hormone (α-MSH), a 13-residue hormone. Its job in the lab is to serve as a benchmark: one well-characterized ligand that activates four of the five melanocortin receptors in cell assays, so new compounds can be measured against it.

    Almost everything useful about the MT2 peptide traces back to that ring. A single lactam bond between aspartic acid and lysine holds the receptor-binding core in one shape, and it also gives the molecule a clean, predictable signature on a certificate of analysis.

    This guide covers the Melanotan 2 structure, its receptor profile, how it’s made, how to read the COA line by line, and its US regulatory status as of November 2026. Life Link Research supplies MT-II for laboratory research use only.

    What Is Melanotan 2?

    Quick answer: Melanotan 2 (MT-II) is a synthetic, cyclic seven-residue analog of alpha-melanocyte-stimulating hormone. It acts as a non-selective agonist at four melanocortin receptor subtypes (MC1R, MC3R, MC4R, MC5R), and researchers rely on it as a reference ligand in receptor-binding and cAMP assays.

    You’ll see the same molecule listed under several names, and they all point to one structure:

    • Melanotan II and MT-II, the forms used in most journal papers
    • MT2 and Melanotan 2, the forms common on supplier catalogs
    • Ac-Nle4-c[Asp5, D-Phe7, Lys10]α-MSH(4-10)-NH2, the systematic name, which numbers each residue by its position in native α-MSH

    The compound came out of Victor Hruby and Mac Hadley’s peptide chemistry program at the University of Arizona. In 1989, Fahad Al-Obeidi and colleagues described a set of cyclic lactam α-MSH analogs designed with molecular dynamics (J Med Chem, 1989), and the Ac-Nle4-c[Asp5, D-Phe7, Lys10] member was the standout. In the group’s in vitro bioassays, it ran roughly 90 times as potent as α-MSH, and a companion 1989 paper from the same group reported that “the cyclic analogue exhibited greater potency, prolonged activity, and stability against enzyme inactivation” compared with its linear twin.

    Those traits are why it stuck around. Decades later, MT-II is still the default agonist dropped into melanocortin assays when a team needs a known, potent positive control.

    What Is the Structure of Melanotan 2?

    Quick answer: Melanotan 2 has the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2. Its six-residue ring is closed by a lactam bond between Asp and Lys, for a formula of C50H69N15O9 and an average mass near 1024.2 g/mol.

    Sequence and the Lactam Bridge

    Read left to right, the sequence has three parts. An acetyl cap and norleucine hang outside the ring. Then come six residues, Asp-His-D-Phe-Arg-Trp-Lys, joined end to side chain: the β-carboxyl of aspartic acid forms an amide with the ε-amine of lysine. The C-terminus finishes as an amide.

    Inside that ring is His-Phe-Arg-Trp, the four-residue motif shared by every melanocortin agonist. In a linear peptide this stretch flops through many shapes. The lactam bridge pins it into a turn, so more of the molecules in a sample hold the shape the receptor recognizes. PubChem’s record counts the result as a 23-membered macrocycle, the ring size the Arizona team singled out in 1989.

    How MT-II Differs from α-MSH

    Featureα-MSHMelanotan 2
    Residue count13, linear7 residues, 6 of them in a ring
    Position 4MethionineNorleucine (Nle4)
    Position 7L-PhenylalanineD-Phenylalanine (D-Phe7)
    EndsAcetyl-Ser1 … Val13-amideAcetyl-Nle … Lys-amide
    RingNoneAsp5-Lys10 lactam

    Each change has a job. Norleucine is a near-copy of methionine with a CH2 group where the sulfur was, so the oxidation site that troubles methionine peptides in storage and analysis is gone. The D-Phe7 swap came from earlier work on NDP-α-MSH and raises receptor potency. Cyclization adds resistance to proteases in in vitro stability assays, the “stability against enzyme inactivation” noted above.

    Melanotan 2 Identity Data

    FieldValue
    NameMelanotan 2 (Melanotan II)
    AliasesMT-II, MT2
    CAS number121062-08-6
    Molecular formulaC50H69N15O9
    Molecular weight (average)1024.2 g/mol
    Monoisotopic mass1023.540 Da
    PubChem CID92432
    FDA UNIIUPF5CJ93X7 (acetate salt: WYE6CXB7CH)
    SequenceAc-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2
    Ring typeSide-chain lactam, Asp5 to Lys10 (cyclic heptapeptide)
    CounterionUsually trifluoroacetate (TFA) or acetate; check the lot’s COA

    Which Receptors Does Melanotan 2 Bind?

    Quick answer: Melanotan 2 binds MC1R, MC3R, MC4R and MC5R with nanomolar affinity in radioligand-binding studies, and shows little activity at MC2R, the ACTH receptor. That broad, potent profile is why MT-II serves as the standard non-selective melanocortin agonist in cell-line assays.

    A 2022 review by Xiao-Chen Yuan and Ya-Xiong Tao in Biomolecules gathered published values for melanocortin ligands at the human receptors and summed up MT-II in one line: “MTII is a nonselective melanocortin agonist with nanomolar to subnanomolar potencies.” Their tables give these figures:

    ReceptorMT-II activityBinding IC50cAMP EC50Study type
    MC1RFull agonist0.2 nM0.2 nMCell line, human receptor
    MC2RNo meaningful activityn/an/aCell line, human receptor
    MC3RFull agonist20 nM0.51 nMCell line, human receptor
    MC4RFull agonist1.5 nM0.05 nMCell line, human receptor
    MC5RFull agonist23 nM5.33 nMCell line, human receptor

    Binding values from Durek et al., 2018, J Med Chem; functional values from Kievit et al., 2013, as compiled by Yuan and Tao (2022). Absolute numbers move between labs with the cell line, radioligand, and assay format, so treat them as a ranking.

    Two patterns show up. Binding is tightest at MC1R and MC4R, and functional potency runs well ahead of binding at MC3R and MC5R, which is typical of strong agonists, where a small share of occupied receptors already drives a full cAMP signal. MC2R is the exception across the board: it answers to ACTH alone and needs its accessory protein MRAP to reach the cell surface, so α-MSH analogs like MT-II barely register there.

    That near-even coverage of four receptors is the reason MT-II earns a place in assay design. A team testing a new MC4R-selective ligand can run MT-II alongside it to confirm every receptor line responds, then read selectivity from the difference in potency.

    MT-II also has a built-in partner. Swapping D-Phe7 for the bulkier D-Nal(2′)7 produced SHU9119, which Hruby and colleagues reported in 1995 as a potent MC3R and MC4R antagonist. One residue separates agonist from antagonist, so MT-II and SHU9119 are often run as a matched pair.

    What Activates MC1R?

    Quick answer: MC1R is activated by its endogenous agonists α-MSH and ACTH, and by synthetic agonists such as Melanotan 2 and NDP-α-MSH. Agouti-signaling protein (ASIP) is the receptor’s natural antagonist and inverse agonist, damping both agonist-driven and baseline signaling.

    MC1R belongs to the rhodopsin-like family of GPCRs and signals through Gs. When an agonist binds, Gs switches on adenylyl cyclase and intracellular cAMP rises. That cAMP rise is the standard readout in MC1R pharmacology.

    In practice, most labs work with the receptor in a host cell line built to express it:

    • Expression systems: HEK293 and CHO cells stably or transiently transfected with human MC1R. Both have low background melanocortin activity, so the signal belongs to the transfected receptor.
    • Binding assays: displacement of a labeled tracer, usually [125I]-NDP-α-MSH, gives IC50 or Ki values.
    • Functional assays: cAMP accumulation measured by HTRF, AlphaScreen or a CRE-luciferase reporter, reported as EC50 and maximal response.

    In these systems, Melanotan 2 at MC1R produces a full cAMP response at subnanomolar concentrations, which makes it a dependable top-of-curve control. ASIP adds a useful twist: because it lowers baseline cAMP as well as blocking agonists, it lets researchers study the receptor’s constitutive activity alongside agonist-driven signaling.

    How Is Melanotan 2 Made?

    Quick answer: Melanotan 2 is made by Fmoc solid-phase peptide synthesis (SPPS). The Asp-Lys lactam is formed by on-resin cyclization, then the peptide is cleaved, purified by preparative HPLC, and lyophilized, usually as a TFA or acetate salt.

    The build runs in a predictable order:

    1. Chain assembly. Starting from a Rink amide resin (which leaves the C-terminal amide), Fmoc-protected amino acids are coupled one at a time: Lys, Trp, Arg, D-Phe, His, Asp, then Nle.
    2. Selective deprotection. Asp and Lys carry side-chain protecting groups that come off under conditions that leave everything else intact. Allyl ester on Asp with Alloc on Lys (removed by palladium) is a common orthogonal pair.
    3. On-resin cyclization. With only those two side chains exposed, a coupling reagent such as PyBOP or HATU closes the lactam while the peptide is still anchored.
    4. N-terminal acetylation, cleavage, and purification. The N-terminus is capped with acetic anhydride, a TFA cocktail releases the peptide and removes the remaining protecting groups in one step, and preparative reversed-phase HPLC isolates the product before freeze-drying.

    Each step leaves its own fingerprints when it falls short:

    • Linear precursor: the ring never closed. Same atoms plus one water, so it shows up about 18 Da heavier.
    • Deletion sequences: a missed coupling drops one residue, lowering the mass by that residue’s weight.
    • Dimers and oligomers: two chains link head to tail during cyclization, roughly doubling the mass.

    Those impurities are exactly what a good COA is built to catch.

    How to Read a Melanotan 2 COA

    Quick answer: A Melanotan 2 COA needs a lot number, an HPLC purity figure with its chromatogram, and a mass-spec result matching about 1024.2 Da. Better COAs also report peptide content and the counterion, so a lab knows how much of the vial weight is MT-II itself.

    Here’s what a complete report for this compound should carry, field by field:

    COA fieldWhat to expect for MT-II
    Compound nameMelanotan 2 / Melanotan II (MT-II)
    Lot or batch numberMatches the vial label
    HPLC purityOne main peak, % area stated, chromatogram attached
    Mass resultObserved ion near 1025.2 ([M+H]+) or 513.1 ([M+2H]2+)
    Peptide contentNet mg or % of vial weight
    CounterionTFA or acetate
    Lab and dateNamed testing lab, test date, signature or report ID

    Any blank row is a question to put to the supplier before the vial goes into an assay.

    HPLC Purity

    Look for one dominant peak in the chromatogram, with small impurity peaks integrated and listed. The purity number is that main peak’s share of total UV absorbance at 210 to 220 nm, and it describes one batch only. A product page can state a target; the certificate states what this lot actually measured. Knowing what 98% vs 99% purity means in real milligrams helps put that one decimal place in proportion.

    Mass-Spec Identity

    HPLC can’t tell you the main peak is MT-II. Mass spectrometry can. With electrospray ionization (ESI-MS), MT-II shows up as protonated ions:

    IonAverage massMonoisotopic mass
    [M+H]+≈ 1025.2≈ 1024.55
    [M+2H]2+≈ 513.1≈ 512.78

    Calculated from PubChem CID 92432 (average 1024.2; monoisotopic 1023.540) plus 1.007 Da per proton.

    A low-resolution instrument usually reports average values; a high-resolution one reports monoisotopic. A peak near 1043 would point to the linear precursor. One trap is easy to miss: a cyclic dimer carrying two protons lands at almost exactly the same m/z as the target ion, so a careful lab checks the isotope spacing (about 1 Da for a single charge, 0.5 Da for a double charge) before signing off on identity.

    Expected ESI-MS values for Melanotan 2 and its most common synthesis impurities, calculated from PubChem CID 92432.

    Expected ESI-MS values for Melanotan 2 and its most common synthesis impurities, calculated from PubChem CID 92432.

    Comparing HPLC vs mass spectrometry side by side shows why a COA needs both: one measures how clean the sample is, the other proves what it is.

    Peptide Content and TFA

    A 10 mg vial is never 10 mg of pure MT-II. Lyophilized peptides carry counterions and some bound water. MT-II’s arginine (and, weakly, its histidine) picks up acid during HPLC purification, so each molecule usually travels with one or two trifluoroacetate ions at 114 Da apiece.

    The arithmetic is quick. One TFA brings the formula weight to about 1138 g/mol, so MT-II itself makes up roughly 90% of that salt. As an acetate salt (60 Da each) the figure rises to about 94%. Add a few percent of bound water and a net peptide content somewhere in the 80s is typical for a TFA salt.

    Lot Match and Lab Check

    Start with the label. Its lot code, compound name, and date need to agree with the certificate exactly. The testing lab’s name and contact details should be on the report, and an independent lab will confirm on request that it issued that report. That independence is the dividing line in third-party vs in-house testing, since a lab with no stake in the sale has no reason to round a result up. Edited dates, recycled batch codes, and mismatched fonts are the usual giveaways, and knowing how to verify a peptide COA end to end makes them quick to spot.

    How Should Lyophilized Melanotan 2 Be Stored?

    Quick answer: Lyophilized Melanotan 2 is best kept sealed at −20 °C, shielded from light, with a desiccant alongside. Bring the still-sealed vial up to room temperature first, so moisture can’t condense on the cold powder when the cap comes off.

    Freeze-dried MT-II holds up well because the two weak points of many peptides have already been designed out: there’s no methionine to oxidize and no free cysteine to pair up. What’s left to manage is moisture, light, and repeated temperature swings.

    • Temperature: −20 °C for long-term storage; a sealed vial tolerates short spells at room temperature in transit.
    • Light: tryptophan absorbs UV, so amber vials or a closed box help.
    • Humidity: a desiccant pack in a sealed bag keeps the cake dry.
    • Handling: reseal promptly and limit freezer-to-bench trips, since each cycle invites moisture.

    The freeze-dried cake is also the reason shelf life runs so much longer in the lyophilized vs pre-mixed peptides comparison: with almost no water present, hydrolysis slows to a crawl.

    Is Melanotan 2 FDA Approved?

    Quick answer: No. Melanotan 2 holds no FDA approval for any use, as of November 4, 2026. US suppliers list it as a laboratory reagent, and it carries an FDA substance identifier, which records identity only.

    Here’s the record, with dates and sources:

    • FDA, 2007: The agency issued a warning letter to Melanocorp Inc. stating that its Melanotan product was an unapproved new drug sold without an approved application, as reported in coverage of the January 2007 letter.
    • FDA, April 22, 2026: FDA’s page on bulk drug substances that may present significant safety risks in compounding lists Melanotan II under “Bulk drug substances nominated but withdrawn,” with a safety-risk note.
    • FDA GSRS: Melanotan II has UNII UPF5CJ93X7 in FDA’s Global Substance Registration System. A UNII identifies a substance; it confers no approval.
    • Skin Cancer Foundation, July 7, 2026: In a statement on Melanotan II, the Foundation wrote that it “is not approved by the U.S. Food and Drug Administration for any use, and its safety has not been established.”
    • Australia’s TGA, January 2023 and May 2026: UNSW Sydney’s January 30, 2023 explainer notes that MT-II isn’t approved for use in Australia, and the TGA later issued 27 infringement notices to an individual for supplying it, which were paid in May 2026.

    Sourcing Melanotan 2 for Research in the US

    A lab ordering MT-II should be able to tick off four checks before the vial goes into the freezer:

    • Batch COA: HPLC purity with chromatogram and an ESI-MS mass near 1025.2 for this lot.
    • Lot match: one batch code shared by vial and report.
    • Third-party lab: a named lab that doesn’t sell peptides and will confirm its report.
    • Shipping: a sealed vial, a short transit time, and temperature control your protocol accepts.

    Life Link Research publishes a batch report on every product page (open the product, then click “View report”), with identity and purity run on every batch by Janoshik Analytical or a US lab. Dispatch is same-day when the order lands before 2 PM PST, going out of California on UPS 2-Day Air. The current lot’s report and specifications for the Melanotan 2 10mg research peptide are published together, and the vial is supplied for laboratory research only.

    FAQs

    Is MT2 the same as Melanotan II?

    Yes. MT2, MT-II, Melanotan 2 and Melanotan II all name the same cyclic peptide, Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, registered under CAS 121062-08-6. The letter forms come from journals and the numeral forms from catalogs. Older papers sometimes write it out in full as the Nle4, D-Phe7 cyclic lactam analog of α-MSH(4-10).

    What is the molecular weight of Melanotan 2?

    The average molecular weight is 1024.2 g/mol for the free peptide (C50H69N15O9), and the monoisotopic mass is 1023.540 Da. Salt forms weigh more: one TFA counterion adds about 114 g/mol.

    What is the CAS number of Melanotan 2?

    CAS 121062-08-6. The same structure appears as PubChem CID 92432 and FDA UNII UPF5CJ93X7, with UNII WYE6CXB7CH for the acetate salt.

    Why is Melanotan 2 cyclic?

    The Asp-Lys lactam holds the His-Phe-Arg-Trp core in the turn that melanocortin receptors recognize. In the original 1989 work, this raised potency well above α-MSH and improved stability against enzymes in vitro.

    Does Melanotan 2 bind MC2R?

    Not meaningfully. MC2R responds to ACTH and depends on its accessory protein MRAP. In cell-line assays, MT-II’s activity stays with the other four subtypes. That one silent receptor makes MC2R-expressing cells a handy negative control in MT-II experiments.

    For Research Use Only. Not for use in diagnostic or therapeutic procedures.

    Life Link Research supplies Melanotan 2 to qualified labs for in vitro study. Full terms are set out in the Life Link research disclaimer.

    References

  • What Is GHK-Cu? Copper-Peptide Chemistry, Structure & COA

    What Is GHK-Cu? Copper-Peptide Chemistry, Structure & COA

    Quick Answer

    GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine (Gly-His-Lys). The peptide holds one Cu²⁺ ion through three nitrogen atoms, which turns the powder blue. It is listed under CAS 89030-95-5 (prezatide copper), and the 1:1 complex weighs about 401.9 to 402.9 g/mol depending on how hydrogens are counted.

    Key takeaways

    • GHK-Cu = Gly-His-Lys bound to one copper(II) ion; free GHK is a white powder
    • Copper is held by the glycine amino N, the Gly-His amide N and a histidine imidazole N
    • 1:1 complex: 401.91 g/mol (neutral) or 402.92 g/mol (CAS 89030-95-5 cation); 2:1 complex: 742.3 g/mol
    • On a COA, mass spec shows free GHK near m/z 341 and the intact complex near m/z 402
    • Also known as copper tripeptide-1 (INCI) and prezatide copper

    GHK-Cu is a copper(II) complex built on glycyl-L-histidyl-L-lysine, a three-amino-acid peptide that holds a single copper ion tightly enough to turn the powder blue. That colour is a quick visual clue, and it’s also the first thing to check when a vial arrives.

    So what is GHK-Cu at the level of atoms and numbers? It’s one of the smallest and best-characterised copper peptides in the research catalogue, with a crystal structure, a PubChem record and a CAS number of its own. It’s also listed with at least three different formulas, which confuses plenty of buyers.

    This guide covers the molecule, how copper binds to it, why those formulas differ, and how to confirm identity on a COA, using our GHK-Cu 75 mg as the example.

    What Is GHK-Cu?

    Quick answer: GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine (Gly-His-Lys). The peptide binds one Cu²⁺ ion through nitrogen atoms in its glycine and histidine residues, forming a blue coordination complex. It was first isolated from human serum in 1973 and is now made synthetically for laboratory research.

    The same molecule carries several names, depending on who’s writing the label:

    • GHK-Cu: the common research name, from the one-letter codes G, H and K plus copper.
    • Copper tripeptide-1: its INCI name, used on cosmetic ingredient lists.
    • Prezatide copper: its nonproprietary name, listed in PubChem under CAS 89030-95-5.
    • Copper peptide or GHK copper: looser labels used by suppliers.

    The origin story is a dated one. Loren Pickart and M. M. Thaler reported the tripeptide from human serum in Nature New Biology in May 1973, and a synthetic version followed in a paper that September. All research material today is synthetic.

    GHK vs GHK-Cu: What’s the Difference?

    Quick answer: GHK is the free tripeptide Gly-His-Lys with no metal bound. GHK-Cu is the same peptide carrying one copper(II) ion. They have different formulas, molecular weights, and CAS numbers, so a COA must state which form the vial contains. “Copper peptide” usually means GHK-Cu, though it can describe other copper complexes too.

    PropertyGHKGHK-Cu (prezatide copper)
    FormulaC14H24N6O4C14H23CuN6O4⁺ (PubChem record for the CAS below)
    Molecular weight340.38 g/mol402.92 g/mol
    CAS49557-75-789030-95-5
    AppearanceWhite to off-white powderBlue to blue-violet powder
    ChargeNeutral recordListed as a +1 cation
    PubChem CID7358771587328

    When a supplier calls its product a GHK-Cu peptide, the copper form is what the label promises, and the CAS number should be 89030-95-5. The quickest field test is colour. A free GHK sample looks like any other white peptide powder, while the copper complex is unmistakably blue.

    GHK-Cu Structure: How Copper Binds the Peptide

    Quick answer: In GHK-Cu, the Cu²⁺ ion is held by three nitrogen atoms from the peptide: the glycine amino nitrogen, the deprotonated amide nitrogen between glycine and histidine, and the histidine imidazole nitrogen. A fourth site is filled by another ligand, which in the crystal is a carboxylate oxygen from a neighbouring GHK. This coordination gives the complex its blue colour.

    Amino Acid Sequence and Stereochemistry

    The sequence runs glycine, histidine, lysine, from the free amino end to the free carboxyl end. Glycine has no side chain and no stereocentre. Histidine and lysine are both the L-form, which gives the molecule two (S) stereocentres, as its IUPAC name records. The lysine side chain ends in a free amino group that stays away from the copper and carries a positive charge.

    Copper Coordination Sites

    The Cu(II) ion rests in a pocket formed by the first two residues. Three nitrogens grip it:

    1. The glycine α-amino nitrogen at the N-terminus.
    2. The amide nitrogen of the Gly-His peptide bond, which loses its proton to bind the metal.
    3. A nitrogen on histidine’s imidazole ring.

    Those three donors and the copper form two small chelate rings, which is why the complex holds together so well. In the X-ray structure reported by Hureau and colleagues in 2011, the fourth position is taken by a carboxylate oxygen from the lysine of a neighbouring complex, giving a square-pyramidal arrangement. In solution, water or other ligands can occupy that position instead.

    GHK-Cu structure, with the three peptide nitrogens that bind copper(II) highlighted.

    GHK-Cu structure, with the three peptide nitrogens that bind copper(II) highlighted.

    Why the Powder Is Blue

    Copper(II) has nine electrons in its outer d orbitals. When nitrogen atoms bind the ion, those orbitals divide into slightly different energy levels. The electrons can jump between them by absorbing visible light from the orange-red end of the spectrum, and the light left over reaches the eye as blue. A powder that looks white or pale grey has little bound copper.

    GHK-Cu Molecular Weight and Formula: 1:1 vs 2:1

    Quick answer: Most suppliers list GHK-Cu as the 1:1 complex, C14H22CuN6O4, with a molecular weight of about 401.9 g/mol. PubChem also lists a 2:1 form (two peptides per copper, C28H46CuN12O8), which has a much higher weight. Check which form a COA reports, because the expected mass-spec value depends on it.

    The confusion comes from hydrogen counting. Binding copper strips protons from the peptide, and each database record counts them differently.

    FormFormulaMW (g/mol)Source
    Free GHKC14H24N6O4340.38PubChem CID 73587
    GHK-Cu 1:1, neutralC14H22CuN6O4401.91PubChem CID 165429100
    GHK-Cu 1:1, cation (CAS 89030-95-5)C14H23CuN6O4⁺402.92PubChem CID 71587328
    GHK-Cu 2:1 (bisprezatide copper)C28H46CuN12O8742.3PubChem CID 9831891

    A fourth figure turns up on some product pages: C14H24CuN6O4 at about 404. That figure is GHK plus one copper atom with no protons removed, a convenient sum that has no database record of its own. The three 1:1 figures, 401.9, 402.9, and about 404, all describe the same complex, so the useful question for any COA is which one the lab used as its reference.

    Physical and Chemical Properties

    PropertyDetail
    AppearanceBlue to blue-violet lyophilized powder
    SolubilitySoluble in water or DMSO for assay preparation
    Storage (powder)-20 °C, dark and dry, in the sealed vial
    MoistureHygroscopic, so let the vial reach room temperature before opening
    pH sensitivityCopper binding depends on pH; strongly acidic conditions protonate the binding nitrogens and release copper

    The pH point is the one that catches people out. Copper binding needs the amide nitrogen to lose its proton, so at low pH the complex comes apart and the blue fades.

    How to Read a GHK-Cu COA

    Quick answer: A GHK-Cu COA should confirm three things. HPLC purity of the peptide, with a chromatogram. Mass-spec identity matching the expected mass for the stated form (1:1 or 2:1). Copper content, by ICP-OES or titration, showing the copper is actually bound. Also check that the lot number, test date, and testing lab match your vial.

    A Life Link Research GHK-Cu COA (MZ Biolabs) with the HPLC and mass-spec results labelled.

    A Life Link Research GHK-Cu COA (MZ Biolabs, lot 2024-06-26) with the HPLC and mass-spec results labelled.

    HPLC Purity

    Look for a chromatogram with one dominant peak and a peak table showing area %, plus the method and detection wavelength. On the earlier MZ Biolabs report pictured above, the GHK-Cu peak elutes at 6.02 minutes and accounts for 99.93% of the area, with one small peak at 5.62 minutes making up the rest. A tiny tripeptide elutes early on reverse-phase columns, so a short retention time is normal here.

    Mass Spec: What Mass to Expect for GHK-Cu

    Electrospray mass spec often shows two signals for GHK-Cu. Some copper falls off in the instrument, so free GHK appears near m/z 341, its protonated mass. The intact complex appears near m/z 402. On the same report, the lab expected a monoisotopic mass of 402.10 Da and measured 402.13 Da. Seeing both peaks is ordinary; seeing only 341 means the copper complex wasn’t confirmed. A copper complex is where HPLC and mass spectrometry diverge most: one reports purity, the other confirms the complex.

    Copper Content and Colour

    Copper content is measured separately, usually by ICP-OES, an elemental analysis method, or by titration. In a 1:1 complex, copper makes up roughly 16% of the mass. A colourless or pale powder suggests free GHK, whatever the label says, so colour and copper content should agree.

    Lot, Date and Lab Checks

    Finish with the paperwork. The lot number on the COA should match the vial label, the test date should fit the batch, and the lab should be named with a way to check the report. Reports issued with a verification key can be confirmed on the lab’s own site. Our guide on how to verify a peptide COA covers all six checks.

    What Is GHK-Cu Studied for in the Lab?

    Quick answer: In laboratory research, GHK-Cu is used as a copper-binding and copper-transport model, and in cell-based assays that measure oxidative-stress markers and extracellular-matrix gene expression. Published work is mostly in vitro and animal studies. Each result applies to its own model and does not show an effect in humans.

    Here’s how the main lines of work divide by study type:

    Assay typeStudy typeReference
    Copper coordination and redox chemistry of the complexIn vitro (chemistry, X-ray)Hureau et al., 2011
    Oxidative-stress markers and peroxiredoxin 6 binding in RAW264.7 macrophage cellsIn vitro and animal (mouse)Bian et al., 2024
    Extracellular-matrix readoutsAnimal (rat)PMID 25731775
    Mitochondrial-function and stress-pathway (DAF-16/SKN-1) assaysAnimal (nematode, C. elegans)Wen et al., 2026
    Gene-expression profiling across cell linesReview of Connectivity Map dataPickart and Margolina, 2018
    Oxidative-stress literatureReviewPickart et al., 2012

    The 2026 nematode study is the newest entry, published in Biogerontology in May. Read each row as a description of the model and the measurement. A result in one cell line or one species belongs to that model, and the table makes no claim beyond it.

    GHK-Cu in Multi-Peptide Blends

    GHK-Cu is often the largest component by mass in multi-peptide blends. In the BPC-157 + TB-500 + GHK-Cu combination, for example, it’s 50 mg beside 10 mg of each of the others. That makes its COA entry easy to overlook. Each component needs its own identity result, and GHK-Cu needs the copper-complex mass near m/z 402, ideally alongside a measured amount. GHK-Cu’s 50 mg share is the largest in the GLOW blend, beside BPC-157 and TB-500. The four-compound BPC-157 + TB-500 + GHK-Cu + KPV kit adds KPV to the same trio, so its documents need four identity results.

    Is GHK-Cu Legal? Regulatory Status in 2026

    Quick answer: GHK-Cu is sold in the US as a research chemical and is used as a cosmetic ingredient under the INCI name copper tripeptide-1. It is not an FDA-approved drug. Research-grade GHK-Cu is sold for laboratory use only.

    The dated record:

    • Drug status: NPR reported on 7 September 2026 that GHK-Cu “isn’t an approved drug,” and topical copper-peptide products have been sold for decades.
    • Compounding: the FDA’s bulk drug substances page, current as of 22 April 2026, lists a GHK-Cu nomination among those withdrawn.
    • Research supply: research-grade material is sold for in-vitro laboratory work under research-use terms.

    Buy GHK-Cu 50 mg with a Batch COA

    Our GHK-Cu comes as 50 mg of blue lyophilized powder per vial. Identity and purity are tested on every batch through Janoshik Analytical and US-based laboratories, with current and earlier reports kept on the product’s certificate page. To find the batch COA, open the product, click View report and match the batch number to the vial label. Orders placed before 2 PM PST ship the same day from California by UPS 2-Day Air.

    FAQs

    What does GHK stand for?

    GHK stands for the three amino acids in the peptide, written in one-letter code: G for glycine, H for histidine, and K for lysine. The full name is glycyl-L-histidyl-L-lysine. Adding “-Cu” marks the form with a copper(II) ion bound to the glycine and histidine end.

    Is GHK-Cu the same as copper peptide?

    Usually, yes. “Copper peptide” on a label almost always means GHK-Cu, also listed as copper tripeptide-1 or prezatide copper. The phrase can technically describe other copper-binding peptides, though, so the sequence Gly-His-Lys and CAS 89030-95-5 on the COA are the reliable identifiers.

    What is the molecular weight of GHK-Cu?

    The 1:1 complex weighs 401.91 g/mol as a neutral formula (C14H22CuN6O4) or 402.92 g/mol as the cation; PubChem links to CAS 89030-95-5. The 2:1 complex, two peptides per copper, weighs about 742.3 g/mol. Free GHK without copper weighs 340.38 g/mol.

    Why is GHK-Cu blue?

    The colour comes from the copper(II) ion. Bound by three nitrogen atoms, copper absorbs light from the orange-red part of the visible spectrum through d-d electron transitions, so the light that remains looks blue. Free GHK without copper is a white powder.

    What should a GHK-Cu COA include?

    A complete GHK-Cu COA shows HPLC purity with a chromatogram and a mass-spec result near m/z 402 for the copper complex. Ideally, it also reports how much copper is present, measured by elemental analysis. Add the usual paperwork: a lot number matching the vial, a test date, and a named, checkable lab.

    How should lyophilized GHK-Cu be stored?

    Store the sealed vial of powder at -20 °C, dry and protected from light. Because the powder pulls in moisture, warm the closed vial to room temperature first and open it only then. A steady blue colour is a simple visual check that the copper complex is intact.

    For Research Use Only. Not for use in diagnostic or therapeutic procedures.

    All products are supplied for in-vitro laboratory research by qualified professionals. Read the full research use disclaimer.

    References

  • Cagri-Reta (Cagrilintide + GLP-3 RT): Composition, Structure & COA

    Cagri-Reta (Cagrilintide + GLP-3 RT): Composition, Structure & COA

    Quick Answer

    Cagri-Reta is a research blend of two synthetic peptides in one vial: cagrilintide, a long-acting amylin analog (4409.0 g/mol), and GLP-3 RT (LY3437943), a GIP, GLP-1 and glucagon receptor triple agonist (4731.34 g/mol). A typical vial holds 10 mg of each, and its COA needs a separate identity and purity result for both.

    Key takeaways

    • Cagri-Reta pairs cagrilintide (Novo Nordisk) and GLP-3 RT (Eli Lilly), usually 10 mg + 10 mg
    • Cagrilintide: 37 residues, C194H312N54O59S2, 4409.0 g/mol, CAS 1415456-99-3
    • GLP-3 RT: 39 residues, C221H342N46O68, 4731.34 g/mol, CAS 2381089-83-2
    • The two bind different receptor families: amylin/calcitonin vs GIP, GLP-1 and glucagon
    • A blend COA should show two resolved HPLC peaks and two mass-spec matches

    Cagri-Reta is a two-peptide research blend of cagrilintide and GLP-3 RT, typically 10 mg of each per vial. The two molecules weigh within about 320 daltons of each other, yet they bind completely different receptor families, and that pairing is the whole reason the blend exists.

    Cagrilintide is a long-acting amylin analog from Novo Nordisk. GLP-3 RT is Eli Lilly’s single-molecule agonist at three receptors. Both are lipidated peptides, both run as large molecules on an HPLC column, and both need their own identity result on a blend COA.

    This guide covers each molecule’s identity and structure, its receptor targets, how to read a two-peptide COA, and where each compound stands in October 2026. Our Cagrilintide + GLP-3 RT 10/10 mg is the example used throughout.

    What Is Cagri-Reta?

    Quick answer: Cagri-Reta is a research blend that combines two separate synthetic peptides in one lyophilized vial: cagrilintide, a long-acting amylin analog, and GLP-3 RT(LY3437943), a single peptide that binds the GIP, GLP-1, and glucagon receptors. Life Link’s version contains 10 mg of each, with its batch documents published on the product’s certificate page.

    The blend travels under several names, which can make catalogues confusing:

    • Cagri-Reta or Reta-Cagri: the two short forms joined, in either order.
    • Reta + Cagri: the same pairing written as two parts, or as plain cagri reta without the hyphen.
    • GLP-3 + cagrilintide: “GLP-3” is an informal nickname for GLP-3 RT, coined because it reaches a third receptor. No receptor called GLP-3 exists.

    Every one of these names points to the same two molecules, and the label should always state the amount of each.

    The reason they’re studied together is simple. Cagrilintide works on amylin and calcitonin receptors. GLP-3 RT works on the incretin and glucagon receptors. Because the two sets of receptors don’t overlap, a single model can carry both signals at once, and a researcher can compare that with either compound alone.

    Cagrilintide vs GLP-3 RT: Side-by-Side Identity Table

    The table below contains the reference identity data for both compounds in one place. Every value comes from a public database or the developer’s own publication, linked below the table.

    PropertyCagrilintideGLP-3 RT
    DeveloperNovo NordiskEli Lilly
    CodeAM833 (also listed as NN0174-0833)LY3437943
    ClassLong-acting amylin analogGIPR, GLP-1R and GCGR triple agonist
    Length37 amino acids39 amino acids
    FormulaC194H312N54O59S2C221H342N46O68
    Molecular weight4409.0 g/mol4731.34 g/mol
    CAS1415456-99-32381089-83-2
    Key modificationsCys2 to Cys7 disulfide bridge; C20 fatty diacid on the N-terminus through a γ-glutamic acid linker; C-terminal proline amideAib at positions 2 and 20; α-methyl-leucine at 13; fatty diacid side chain on Lys17 through a linker
    Receptor targetsAmylin receptors AMY1, AMY2, AMY3 and the calcitonin receptorGIP receptor, GLP-1 receptor, glucagon receptor

    Sources: cagrilintide formula, weight, CAS, and structure from PubChem CID 171397054 and its design paper (Kruse et al., J Med Chem, 2021). GLP-3 RT formula, weight, sequence, and targets from KEGG D12430; its Lys17 acylation site from the receptor-structure study by Li et al., Cell Discovery, 2024.

    Cagrilintide vs retatrutide identity data: formula, molecular weight, CAS and receptor targets

    Cagrilintide and GLP-3 RT identity data side by side, with what a blend COA should show.

    Two details from the table come up again on any blend COA. The weights differ by roughly 322 Da, which lets a mass spectrometer tell the two apart without trouble. And both molecules carry a fatty side chain, so both behave as greasy, slow-eluting peptides on a reverse-phase HPLC column.

    What Is Cagrilintide?

    Quick answer: Cagrilintide is a synthetic, long-acting analog of the hormone amylin, developed by Novo Nordisk. It is a lipidated peptide with a disulfide bridge, and it binds amylin receptors (AMY1, AMY2, and AMY3) and the calcitonin receptor. In research, it is studied as a receptor-binding and assay tool; it has no FDA approval as a standalone product.

    Structure and Modifications

    Cagrilintide is 37 amino acids long and starts from the amylin sequence. A disulfide bridge between Cys2 and Cys7 closes a small ring near the N-terminus, the same ring native amylin carries. The C-terminal half contains three prolines at positions 25, 28, and 29, and the chain ends in a proline amide.

    The long-acting part comes from lipidation. A C20 fatty diacid is attached to the N-terminal lysine through a γ-glutamic acid linker. Novo Nordisk’s chemists described that design choice in their 2021 development paper.

    Receptor Targets: AMY1-3 and the Calcitonin Receptor

    Amylin receptors are built from two parts. The calcitonin receptor (CTR) pairs with one of three receptor activity-modifying proteins, RAMP1, RAMP2, or RAMP3, to form AMY1, AMY2, and AMY3. Cagrilintide activates all three as well as CTR on its own.

    In cell assays, binding is usually read out as cAMP, the second messenger these receptors raise. Researchers express CTR with or without a given RAMP and compare cAMP responses across those cell lines to map a ligand’s receptor profile. A single-compound cagrilintide 5 mg vial suits that kind of side-by-side assay.

    What Is GLP-3 RT?

    Quick answer: GLP-3 RT (LY3437943) is a 39-amino-acid synthetic peptide developed by Eli Lilly. One molecule activates three receptors (GIPR, GLP-1R, and the glucagon receptor), which is why it is called a triple agonist. It carries a fatty-acid side chain for albumin binding. As of 31 October 2026, it is investigational and not FDA approved.

    Structure: Aib Substitutions and Lipidation

    GLP-3 RT’s sequence reads YXQGTFTSDYSILLDKKAQXAFIEYLLEGGPSSGAPPPS, where each X is Aib (α-aminoisobutyric acid). The Aib at position 2 resists cleavage by the DPP-4 enzyme, and a second Aib appears at position 20. Position 13 carries α-methyl-leucine, another non-natural residue.

    The fatty diacid side chain is attached to Lys17 through a linker. That side chain lets the peptide bind albumin reversibly. Lilly’s discovery team set out the design in Cell Metabolism in 2022.

    Triple Receptor Binding (GIPR / GLP-1R / GCGR) in Assay Terms

    All three of GLP-3 RT’s receptors belong to the class B GPCR family, and all three raise cAMP when activated. That makes them easy to compare in the same assay format. Researchers typically use cell lines that express a single human receptor each and measure cAMP across a range of concentrations.

    Those concentration-response curves show how potent the peptide is at each receptor relative to the native hormones, GIP, GLP-1, and glucagon. Cryo-EM structures published in 2024 show how one ligand fits all three binding pockets. For single-compound work, a GLP-3 RT 15 mg vial keeps the triple agonist on its own.

    Why Are Cagrilintide and GLP-3 RT Researched Together?

    Quick answer: Researchers pair them because they act on different receptor families: amylin/calcitonin receptors for cagrilintide, and incretin/glucagon receptors for GLP-3 RT. This lets studies compare single-receptor and multi-receptor signaling in one model. The combination itself has so far been described only in animal work, while each molecule has its own separate research history.

    The evidence comes in two clearly separate piles:

    • The combination: one published study, in rats. Petersen and colleagues reported it in Nature Metabolism in October 2026, and it remains the only peer-reviewed paper on this exact pairing.
    • Cagrilintide alone: its own development line at Novo Nordisk, from in vitro receptor work through a human clinical programme.
    • GLP-3 RT alone: its own programme at Eli Lilly, from receptor pharmacology through Phase 3 human trials.

    In assay terms, the pairing makes a tidy experiment. One ligand reaches receptors built from CTR and RAMPs, the other reaches three class B GPCRs, and all of them raise cAMP. That shared readout lets a researcher measure both signals the same way and see how they combine.

    So a blend of the two draws on two long, separate histories and one new animal study of them together.

    Blend vs Separate Vials

    A cagrilintide GLP-3 RT blend in one premixed 10/10 mg vial and two single vials hold the same molecules. They suit different study designs.

    FeatureCagri-Reta blend (one vial)Two single vials
    ConsistencyBoth peptides come from one mixing step, so every vial in the batch shares the same pairingEach compound has its own batch
    DocumentationOne COA covers both compoundsTwo COAs, one per compound
    Study designBuilt for work that needs both compounds togetherLets each compound run alone as well as together

    Separate vials make controls easier, since a study can run cagrilintide alone, GLP-3 RT alone, and both together from known lots. The blend keeps handling simple, with one vial and one document to track per batch. Blends versus single vials is a different decision from which compounds to pair.

    How to Read a Cagri-Reta COA

    Quick answer: A Cagri-Reta COA should show two separate identity and purity results, one for each peptide. Look for two resolved HPLC peaks, a mass-spec match for each compound’s expected molecular weight (about 4409 and 4731 Da), the content of each per vial (10 mg + 10 mg), and a lot number matching your vial.

    A single GLP-3 RT COA has one molecule to prove. A blend report has two, and it has to show each one in the right amount.

    Two HPLC Peaks and Resolution

    On a single-peptide chromatogram, purity is the main peak’s share of the total area. A blend chromatogram should show two main peaks, one per compound, each with its own retention time. They need to be resolved, meaning separated down to the baseline, so each area can be measured cleanly. Two merged peaks reported as a single percentage can’t tell you how pure each component is. Both molecules carry fatty side chains and tend to elute late, so a method that separates them cleanly shows the lab tuned it for this blend.

    MS Confirmation for Each Peptide

    Mass spectrometry confirms that each peak is the molecule it should be. Look for two observed masses, one near 4409 Da for cagrilintide and one near 4731 Da for GLP-3 RT, each within the lab’s stated tolerance. Large peptides often show up as several charge states, which the lab converts to a single mass. The amount of each peptide per vial comes from a separate measurement against a reference standard, reported in mg. Purity and identity are separate questions on a blend certificate, which is why HPLC and mass spectrometry both appear on it.

    Lot, Date and Lab Checks

    The paperwork checks are the same as for any peptide. Match the lot number to the vial label, confirm the test date fits the batch, and verify the report with the lab using its key or QR code. For a blend, also confirm the sample line names both compounds and both amounts, since a report for either single peptide can’t stand in for the blend. Our step-by-step guide on how to verify a peptide COA walks through all six checks.

    Is Cagri-Reta FDA Approved?

    Quick answer: No. As of 31 October 2026, neither the Cagri-Reta blend nor GLP-3 RT on its own is FDA approved. GLP-3 RT remains investigational with Eli Lilly, and cagrilintide is in development with Novo Nordisk, including as part of CagriSema. Research blends like Cagri-Reta are sold for laboratory research use only.

    Here’s the dated record behind that answer:

    DateEventSource
    Aug 2021Novo Nordisk chemists publish cagrilintide’s designJ Med Chem
    Sep 2022Lilly scientists describe the discovery of LY3437943Cell Metabolism
    18 Dec 2025Novo Nordisk submits a New Drug Application to the FDA for CagriSema (cagrilintide with GLP-1 SM)Novo Nordisk
    23 Jul 2026Lilly reports Phase 3 TRIUMPH-2 and TRIUMPH-3 results and plans a Biologics License Application for GLP-3 RT in Q1 2027Eli Lilly
    Oct 2026First peer-reviewed study of the cagrilintide and GLP-3 RT combination, in ratsNature Metabolism

    Status lines change, so each one here carries a date, and this table is updated when Lilly, Novo Nordisk, or the FDA announces the next step. For the other cagrilintide pairing, see what is CagriSema.

    Storage and Handling of the Lyophilized Blend

    Keep the sealed vial of lyophilized powder at -20 °C, protected from light. Both peptides are large and lipidated, so the powder is best kept dry and cold until the day of the assay. Let the vial reach room temperature before opening it, so moisture doesn’t condense on the powder. The blend is soluble in water or DMSO for assay preparation. Note the batch number and the date the vial arrived, so every assay result can be traced back to its COA.

    Buy Cagri-Reta 10/10 mg with a Batch COA

    Our Cagri-Reta vial holds 10 mg of cagrilintide and 10 mg of GLP-3 RT, tested through Janoshik Analytical, an independent lab that issues each report with a verification key. Identity and purity are tested on every batch, with heavy metals, endotoxin, and sterility run on a rotating cycle. To look up the batch COA, open the product, click View report, and match the batch number to your vial label.

    Orders placed before 2 PM PST ship the same day from California by UPS 2-Day Air, with free shipping over $250. Every purchase is for qualified laboratory research under our research-use terms.

    FAQs

    What is Cagri-Reta?

    Cagri-Reta pairs two synthetic peptides in one vial: cagrilintide, Novo Nordisk’s lipidated amylin analog, and GLP-3 RT (LY3437943), Eli Lilly’s GIP, GLP-1, and glucagon receptor triple agonist. A typical vial holds 10 mg of each. It is supplied for laboratory research only.

    What does “10/10 mg” mean on a Cagri-Reta vial?

    Each vial contains two 10 mg portions, one of each peptide, for 20 mg of peptide in total. The first number is cagrilintide and the second is GLP-3 RT. A blend COA should report each amount separately, so you can confirm both figures for your batch.

    Is GLP-3 RT a GLP-1 agonist?

    Yes, and more. GLP-3 RT activates the GLP-1 receptor, the GIP receptor, and the glucagon receptor, all from one molecule. That’s why it’s called a triple agonist, and it’s the source of the informal “GLP-3” nickname. All three targets are class B GPCRs that raise cAMP in cell assays.

    What is the molecular weight of cagrilintide and GLP-3 RT?

    Cagrilintide has a molecular weight of 4409.0 g/mol (C194H312N54O59S2, CAS 1415456-99-3). GLP-3 RT weighs 4731.34 g/mol (C221H342N46O68, CAS 2381089-83-2). The difference of about 322 Da lets mass spectrometry tell the two apart on a blend COA.

    How do I verify a Cagri-Reta COA?

    Match the lot number on the report to the vial label, then check the test date and the lab. Enter the report’s verification key on the lab’s own website. Finally, confirm the COA lists a separate result for each peptide, ideally two resolved HPLC peaks and two mass-spec matches.

    Is Cagri-Reta FDA approved?

    No. The FDA has approved neither the blend nor GLP-3 RTby itself, and that holds at the end of October 2026. Lilly plans to file for GLP-3 RT in Q1 2027, and Novo Nordisk filed CagriSema, which pairs cagrilintide with GLP-1 SM, in December 2025. Cagri-Reta is sold for laboratory research use only.

    For Research Use Only. Not for use in diagnostic or therapeutic procedures.

    All products are supplied for in-vitro laboratory research by qualified professionals. Read the full research use disclaimer.

    References